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 As patient engagement in research becomes increasingly common, it has grown 
important to develop best practices for its use.  One aspect of patient engagement that 
remains empirically and conceptually under-explored is how to identify the appropriate 
patients to partner with for patient engagement in research.  The limited available 
evidence suggests that researchers often partner with patient advocacy organizations 
(PAOs).  Yet little is known about whether patient advocates have experiences and views 
of research that differ from those of patients who are uninvolved in advocacy work, and 
from a normative perspective, it is unclear whether and why it might matter if they did.  
 This dissertation seeks to advance our understanding of these issues by exploring 
whether individuals who are involved in patient advocacy work have different 
experiences and beliefs about research than patients who are not involved in advocacy, 
and how patients' beliefs about research are related to their degree of advocacy 
involvement in general.   To explore these topics, interviews were conducted with parents 
of children who have one of three rare disorders: Childhood cerebral 
adrenoleukodystrophy, Duchenne muscular dystrophy, or sickle cell disease.   The 
context of rare disease was chosen as a focus for this study because parents of children 
with rare diseases have been especially active in the research space over the past thirty 
years and little is known about how they view research.   
 The results of this dissertation are reported in three papers.  The first paper 
explores the views that parents of children with rare diseases have about research and 
medicine in general, and their views related to biorepository research specifically.  The 
findings reported in paper one suggest that parents who were patient advocates and 
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parents who lacked advocacy involvement had few systematically different experiences 
or beliefs about research, but that parents' views differed based on the nature of the 
condition their child had. 
 Paper two focuses on parents' experiences and beliefs related to patient advocacy.  
The second paper demonstrates that parents who are involved in patient advocacy were 
motivated to become involved because it helped them cope with their child's condition 
and because they wished to use their professional skills to help others.  Parents who were 
uninvolved in advocacy cited the demands of caregiving, negative prior experiences, or a 
desire for privacy and space as reasons.  Most parents believed that partnering with PAOs 
was a good strategy for researchers to use to engage patients, but some were concerned 
that marginalized patients may not be reached that way. 
 The third paper explores whether and why it might matter, from a normative 
perspective, if the volunteers who participate in patient engagement initiatives differ from 
patients who are uninvolved.  Drawing upon existing literature and findings from my 
empirical study, paper three evaluates whether instrumentally or intrinsically worthy aims 
of patient engagement might be affected by differences between engaged volunteers and 
unengaged patients, and whether patient engagement should be considered a 
representative exercise in the first place.  Paper three concludes that for ethical reasons, 
patient engagement efforts should endeavor to represent the experiences, values, and 
attributes of patients who are not engaged in research but that practical constraints also 
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MANUSCRIPT 1: Experiences with and attitudes toward pediatric biorepository 
research among parents of children with rare diseases:  A comparison of parents 




Background: In the United States, there is a growing emphasis on patient engagement in 
research. In research for rare diseases, patients who participate in patient engagement are 
often patient advocates.  Little is known about how patients affected by rare diseases 
experience and view research, and in particular, it is unclear whether patient advocates' 
experiences and views of research differ from those of patients not involved in advocacy 
work. Methods: This qualitative interview study collected data about the experiences and 
views of parents of children with rare diseases (N=34) related to medicine and research.  
Interviews were audio-recorded, transcribed, and thematically analyzed using a primarily 
deductive approach.  Results: Few differences were found in the experiences and views 
of parent advocates compared with non-advocate parents.  Overall, most parents 
preferred to hear about research from physicians they trusted and felt respected by.  Most 
parents did not believe re-consent was necessary for secondary research uses of their 
child’s health data.  Parents held divergent opinions about research priorities, the optimal 
time of biorepository recruitment, and the acceptability of having their child’s data used 
in research for conditions other than their own.  Conclusion:  Parents’ views appeared to 
be more related to the nature of their child’s condition or their demographic background 
than to their degree of advocacy involvement.  Future studies should explore disease- and 
population-specific differences in beliefs about research with a view to their implications 




 In the United States, there is a current trend of growing investment in patient 
engagement in research. Examples include work funded by the Patient-Centered 
Outcomes Research Institute (PCORI), the Patient-Focused Drug Development Initiative 
at the Food and Drug Administration (FDA), and plans to engage the public as part of the 
Precision Medicine Initiative (PMI)1–3.  Increased patient engagement is motivated by a 
belief that involving patients in multiple aspects of research, including planning, 
execution and results dissemination, can improve the relevance of research and express 
respect to study participants4,5.   
 Often, in seeking to engage patients, researchers turn to patient advocates as 
partners6. One unexplored question is whether patient advocates have experiences with 
and views about the research enterprise that differ from those of patients who aren’t 
involved in advocacy work.  The work presented in this paper is drawn from a larger 
project that interviewed advocate and non-advocate parents of children with rare genetic 
diseases in order to learn about their experiences and views of research and of disease 
advocacy.  The data presented in this paper examine whether parents’ experiences with 
advocacy are related to their attitudes about research in general and biorepository 
research in particular.   Discussed elsewhere is the degree to which parents’ views about 




 Rare diseases are defined as those that affect <200k people in the United States7.  
Many rare diseases are disabling or life-limiting, and an estimated 80% of them are 
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significantly influenced by genetic factors. Since rare diseases by definition affect small 
numbers of patients, it is challenging to study them, and many clinical trials of rare 
disease therapeutics are halted early when they fail to demonstrate significant effects on 
study outcomes in  early trial stages 8,9.   Since there are few treatments for rare diseases, 
rare disease patient advocacy organizations have been highly active since the early 1980s 
in advocating, fundraising and building infrastructures for biomedical research, especially 
genomic research10,11.  Many of these organizations are run by parents of affected 
children12.   
 Given the role that genetics plays in the etiology of many rare diseases, rare 
conditions are often studied using registries and biorepositories that aggregate 
information from geographically-dispersed families.  These registries and biorepositories 
generally collect genetic and phenotypic data for future observational and natural history 
studies13.  This type of database-driven research, while efficient for research learning, 
also raises controversial policy questions about informed consent and data stewardship.  
Such questions include how research participants should be recruited to contribute data 
and biospecimens, whether and when it is necessary to obtain repeat informed consent for 
the use of a research sample in a study unrelated to the one for which it was originally 
obtained, and for which purposes a research database should be used 14–16.  As large 
investments are being made in national research databases to study both rare and 
common diseases,17,18 patient engagement is being used as a tool to help answer these 
questions.  Increasingly, patient engagement is being viewed as key to the success and 
ethical conduct of research using large datasets containing personal data19.    
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 One challenge related to patient engagement is the lack of guidance about how to 
identify the individuals or organizations with whom researchers should partner4.   In a 
systematic review of approaches for engaging patients in rare disease research, Forsythe 
and colleagues found that rare disease patient advocacy organizations are often used as 
partners or intermediaries6.  While an efficient strategy for finding partners, it remains 
unclear whether rare disease patient advocates have experiences and views about research 
that differ from those of parents not involved in patient advocacy.  Such information 
would shed light on whether patient advocates are well-positioned to represent the views 
and interests of all patients and their families related to research, or indeed, whether this 
ought to be the expectation we have of them.   
 This paper reports the findings from a qualitative interview study designed to 
address this question.  Interviews were conducted with parents (N=34) of children who 
had one of three rare pediatric-onset genetic disorders:  Childhood cerebral 
adrenoleukodystrophy (CALD), Duchenne muscular dystrophy (DMD), or sickle cell 
disease (SCD).  Parents were purposively sampled to include 1) parents who have held 
formal roles in patient advocacy organizations, either currently or in the past, and 2) 
parents with no advocacy experience.  Parent advocates’ and non-advocate parents’ 
experiences and views about general and biorepository research were compared. Data 
analysis also explored how parents’ views were related to the condition their child(ren) 







 The objectives of this qualitative interview study were 1) to characterize the 
experiences and attitudes of parents of children with rare diseases with respect to research 
for their child’s condition and 2) to compare the experiences and views of parents who 
have had formal roles in advocacy with the views of parents who have not been involved 
in advocacy work.  In-depth interviews were conducted over the phone with parents of 
children with CALD, DMD, or SCD.  A qualitative descriptive approach was used, 
aiming to comprehensively describe the phenomenon under investigation20.  This study 
was approved by the Johns Hopkins Bloomberg School of Public Health Institutional 
Review Board (JHSPH IRB).  
 
Sampling and Recruitment 
 
 The characteristics of the three diseases affecting children of parents in this study 
are described in Table 1.0 and detailed more extensively in Appendix 2: Extended 
Methods for Empirical Study. Childhood cerebral adrenoleukodystrophy (CALD) is a 
progressive neurodegenerative condition affecting mostly boys, which typically results in 
death between ages seven and fifteen.   Duchenne muscular dystrophy (DMD) is a more 
slowly progressive muscle disorder affecting mostly boys which involves a loss of 
ambulation, cardiomyopathy, and respiratory decline, leading to death between the 
second and fourth decades of life.   Sickle cell disease (SCD) is a chronic hematological 
disorder affecting both boys and girls which is more common in individuals of Asian and 
African descent.  It involves pain crises, recurrent infections, strokes, and pulmonary 
hypertension.  Affected individuals typically live into their fourth or fifth decades of life. 
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   Purposeful sampling was used across three disease groups with the goal of 
identifying and recruiting parents who had assumed roles in patient advocacy 
organizations and parents who had never had such advocacy roles for the purpose of 
comparing their views. Eligible parents were English-speaking, residents of the United 
States with one or more affected children currently aged 0-25, or whose affected 
child(ren) were 0-25 years of age when they died.    Eligible parents were notified about 
this study in one of three ways:  1) An e-mail sent to them by a patient advocacy group 
for their child’s condition, containing a link to an online screening questionnaire (see 
supplemental materials); 2) A flyer distributed in clinics at Johns Hopkins Hospital or 
Kennedy Krieger Institute, containing a link to the screening questionnaire, or 3) word of 
mouth from patient advocacy group leaders who agreed to help with study recruitment.  
The CALD and DMD patient advocacy groups that agreed to help with study recruitment 
were based throughout the continental United States.  The SCD advocacy groups that 
agreed to help were in the Greater New York and Mid-Atlantic regions. 
 The online screening questionnaire was designed to learn about the nature and 
degree of parents’ advocacy involvement, in order to select both advocates and non-
advocates for recruitment.  The screening questionnaire also included questions about 
parent demographics, child well-being, and the types of research parents had pursued for 
their children, to assist with efforts to build a varied sample of parents in each group. For 
parents not recruited online (e.g., through advocacy organizations or clinics), the 
demographic/background information obtained from screening questionnaires was asked 





 Oral informed consent was obtained before each interview. All interviews were 
audio-recorded and transcribed either by the interviewer (LJ) or by a professional 
transcription service.   The interviews followed a guide exploring parents’ experiences 
seeking medical care for their child, experiences with and beliefs about research, 
experiences with patient advocacy organizations, attitudes toward advocacy, and views 
about four aspects of biorepository-based research:  informed consent for secondary re-
use of their child’s research data, research recruitment, research uses of children’s data, 
and their beliefs about researcher trustworthiness. 
 Before the study began, two cognitive interviews were conducted with parents of 
children with rare diseases other than CALD, DMD, or SCD.  The interview guide was 




 Interviews were conducted until informational redundancy was reached.  Data 
collection and analysis occurred iteratively using a primarily deductive.  The initial 
coding scheme was developed based on the study’s research questions and domains and 
questions in the interview guide.  Some inductive codes were added as new themes 
emerged.  To ensure reliability, a second coder was trained who coded four transcripts 
independently from the interviewer/lead investigator (LJ).  Double-coded transcripts were 
reviewed and any discrepancies discussed and resolved, and clarifications made to the 
codebook.  After all transcripts were coded manually, the coded text was entered into 





 The results of this study will be reported in the order they were discussed in the 
interview.  First, participants' characteristics and prior experiences in medicine will be 
reported.  Subsequently, their general attitudes to research and specific attitudes to 




  Interviews were conducted with 34 parents (12 parents of children with CALD, 
12 parents of children with DMD, and 10 parents of children with SCD).  Sixteen parents 
described having an active formal role in patient advocacy (“parent advocates”), and 18 
described having done little to no prior advocacy work (“non-advocate parents”).  
Interviews lasted 40-65 minutes. 
 Participants’ self-reported background characteristics are summarized in Table 
1.1 and 1.2. All participants had at least some college education, although more than one-
fourth (n=10) had not completed their undergraduate degree.  Half of the parents (n=6) 
from the CALD group had lost their child to the disease; only one other parent had lost 
their child (DMD, n=1). 
 Parent advocates were, on average, older, more likely than non-advocate parents 
to hold a graduate degree and more likely to have had their child diagnosed more than ten 
years prior to the interview.   
 Parents of children with DMD reported the most research involvement, with 
nearly half (n=5) of DMD parents reporting that they had enrolled their child in a 
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randomized clinical trial and two-thirds (n=8) reporting they had enrolled their child in a 
registry or another form of observational research.  In the CALD and SCD cohorts, no 
parents reported having enrolled their child in a randomized clinical trial, although a 
quarter of CALD (n=3) participants and one SCD participant reported enrolling their 
child in another type of clinical trial.  More than half (n=7) of SCD parents reported 
never having enrolled their child in a research study of any sort. The advocacy roles held 
by parent advocates are summarized in Table 1.3.   
 
Experiences in Medicine 
 
 Half of all parents (n=16) expressed some kind of complaint about their 
experiences with their child’s clinical care.  No notable differences were evident between 
the comments of parent advocates and non-advocate parents.   However, parents’ 
complaints about medical care did differ by disease group.  Parents of children with 
CALD or DMD were more likely to voice concern about having noticed their child’s 
symptoms before their pediatrician did (CALD =8 of 12; DMD n=8 of 12) or to report 
experiencing a protracted diagnostic odyssey.  Most CALD parents (CALD n=10 of 12) 
reported that their child had been misdiagnosed with ADHD, and that the correct 
diagnosis was reached “too late”.  By contrast, SCD parents reported being dismissed or 
mistreated when seeking help to alleviate their children’s pain (SCD n=8 of 10).  Some 
SCD parents (SCD n=4 of 10) also reported that they had experienced racial 
discrimination in healthcare.   
 Slightly more than a third of parents in the overall sample (n=12) expressed 
positive views about their experiences in medicine, with four of these parents expressing 
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a mixture of positive and negative views.  Again, no notable differences were evident 
between advocates and non-advocates or among the three disease groups.   The most 
common positive theme was that parents had established close bonds with the primary 
medical specialists following their child.  Parents reported high levels of trust and 
attachment to healthcare providers specializing in their child’s condition, whether that 
provider was a physician, physical therapist, or palliative care specialist. 
 
Experiences and Beliefs About Research in General 
 
 When asked about their experiences and beliefs about research in general, most 
parents understood the term “research” to refer to a clinical trial. Across all three groups, 
a majority of parents (n=24) reported that they learned about research from the medical 
specialist managing their child’s condition.  In most of these instances parents reported 
that their doctor initiated a discussion with them about research, although in a handful 
(n=4) of cases parent advocates (but no non-advocates) described asking their doctors 
about research first.  
 Roughly half (n=18) of parents in the overall sample asked the interviewer what 
research is available for their child’s condition or expressed some confusion about 
research for their child’s condition.  Nearly all of these parents (n=17) specifically 
expressed confusion or concern about their child’s eligibility for existing studies.  Some 
parents in each disease group (n=10) also mentioned the challenges of conducting 
research for rare diseases, including small sample sizes and lack of adequate funding.  
There were no notable differences in the prevalence of these themes between advocates 
and non-advocates or across disease groups.   
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 There were few differences in themes mentioned by parent advocates and non-
advocate parents.  However, parent advocates in the DMD and CALD cohorts were more 
likely to volunteer opinions about U.S. federal research policy than non-advocate parents.  
Of the 12 parents who voiced opinions about research policy, nine were advocates for 
either DMD or CALD.  By contrast, only three non-advocate CALD or DMD parents 
voiced unsolicited opinions about federal research policy.  No SCD parents discussed 
federal research policy.    
 Parent advocates who did volunteer opinions about research policy spoke about 
the Food and Drug Administration (FDA)’s evidence thresholds for rare disease drug 
development, the interpretation of the Common Rule by Institutional Review Boards, and 
the challenges to research recruitment posed by the Health Insurance Portability and 
Accountability Act (HIPAA).  These parents all voiced some frustration with existing 
policies, for example: 
 
My son would be eligible for the next round of the exon skipping, but it’s been a 
frustrating process to see, again, how the FDA says you've got to send your child 
up this way, and the study has to be placebo-controlled. At the site I was working 
with in [ACADEMIC MEDICAL CENTER NAME]- they put in a new protocol that 
the drug company had done with FDA guidance and that IRB had major issues with 
some of the procedures in the control arm. So they are further delaying now, and 
now we can't go get screened. So this has been a back and forth of feeling like, 
you're damned if you do it the FDA way, and you’re damned if you don't…there's 
all this natural history data, a set disease progression model that they're not using, 
and then you have an example like this with a local IRB fretting about child 
research, questioning whether it is ethical to give a child a biopsy. If anything else 
is it unethical to keep him not on the drug.  –DMD261 (parent advocate) 
  
 Some experiences and beliefs were more closely related to which condition a 
parent’s child had, rather than their degree of advocacy involvement.  DMD parents were 
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most likely (DMD n=10 of 12) to describe their child’s research participation as 
burdensome, while fewer CALD parents (CALD n=3 of 12) expressed this view, and no 
SCD parents mentioned it.  Research burdens mentioned included the effort in travel, the 
discomfort of study procedures, the disruption of a child’s normal routine, and the costs 
of study participation, which were not always reimbursed.   
 Parents in the SCD cohort were more likely to articulate concerns about the risks 
of research than parents of children with either CALD or DMD (SCD n=7 of 10; CALD 
n=2 of 12; DMD n=2 of 12). Some of these parents said they would be willing to enroll 
their children in risky research only if their children were not faring well: 
 
So if I have a situation where my daughter was so chronically ill, that you know 
her quality of life was just poor, I would then maybe consider it. Although I don’t 
know if that would violate the protocol or not, if they are that sick if they can even 
be in a study.  But I think she would have to be so sick to the point of never being 




 Parents of children with SCD and DMD (SCD n=5 of 10; DMD n=3 of 12) also 
cited a desire to preserve their child’s future decision-making autonomy as a reason for 
not enrolling their child in research.   These parents valued their children's right to make 
their own decisions about research later on.  No CALD parents mentioned this theme. 
 
Beliefs About Specific Practices in Biorepository Research 
 
 This section describes parents’ views about biorepository recruitment, re-consent 
for secondary research uses of data, acceptable uses of research data, and the 
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trustworthiness of researchers.   For each topic, differences in views related to parents’ 
advocacy involvement and the disease their child(ren) had are reported.   
 
Views about Recruitment 
 Most parents (n=30) said they would prefer to be asked to contribute their child’s 
health information to a research biorepository by their child’s doctor.  Parents who 
believed this were roughly equally split across disease groups and were roughly equally 
likely to be parent advocates or non-advocate parents.  Many parents said they believed it 
would be best to hear about a research biorepository from their child’s doctor because he 
or she was an individual with whom they had a familiar, trusting relationship and who 
could answer questions: 
 
 It would have to be coming from someone I trust and can ask questions in 
person.  If [physician name] and the other doctors at [hospital name] really 
supported it, I would trust that it was helpful and legitimate.  If it was some 
company that I never heard of I would probably just throw away the flyer or 
delete the email.  -ALD122 (non-advocate parent) 
  
 A minority of parents (n=5) said they would prefer to be invited to contribute their 
child’s data to a research biorepository by e-mail, phone, or social media.  One parent 
was skeptical about the merits of recruiting parents via their doctors in clinics, because of 
her perception that hospitals can be inefficient and disorganized: 
 
 I mean, the thing about reaching me through my doctor is that different 
hospitals operate differently with varying degrees of success.  My son’s 
neurologist had MRI results that said he had CALD for four days before calling 
me.  I don’t think she actually saw it, but the office didn’t get it to her….so by 
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reaching out to doctors, sometimes, I think you’re not always going to get the 
patients.  –CALD140 (non-advocate parent) 
 
 Overall, roughly one third (n=11) of parents believed that it would be acceptable 
or even desirable to be recruited soon after their child’s diagnosis, while almost as many 
believed it would not be acceptable or would be a bad idea (n=9).  Roughly equal 
proportions of parent advocates and non-advocate parents believed that recruitment soon 
after diagnosis would be acceptable or desirable; fewer parent advocates (n=3 of 16 
parent advocates) than non-advocate parents (n=6 of 18 non-advocate parents) believed it 
would be an unacceptable or bad idea.  
 Some parents who felt it would be desirable to be told about a research 
biorepository soon after their child’s diagnosis explained that it would have been 
comforting to know that researchers are interested in their child’s disease.   Other parents 
said that they thought recruitment soon after diagnosis was important in order to capture 
complete data about the natural history of their child’s condition.  Irrespective of their 
own views, several of these parents acknowledged that other parents could reasonably 
disagree:    
 
 There are definitely different personality styles and coping styles that 
come into play.  Some people are more private than others, some people are more 
suspicious than others, and some people do not cope well, with, you know – 
talking about Duchenne.  For those that don’t want to hear about it in the early 
stages for those reasons, that makes sense. -DMD236 (parent advocate) 
 
 Parents who believed it would be unacceptable or a bad idea to be recruited soon 
after their child’s diagnosis said they would have been emotionally unprepared to process 
information about research participation at that time.  A handful of parents who felt that 
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recruitment soon after their child’s diagnosis would be a bad idea said that the 
appropriate time for recruitment should be assessed on a case-by-case basis.  This theme 
was related to the common belief that physicians are ideally situated to approach parents 
about research: 
 
 I think the neurologist would know best when to approach you 
emotionally.  You know, they are in a position to say, ‘is she someone I should 
approach at this point?  Probably not, but maybe in a couple of years, this would 
be someone you can approach and she will really understand and get it’.  So 
that’s another reason that the doctor would be better than an e-mail.  I think an e-
mail is… like, screw you, there’s no way I’m giving anyone permission to take my 
kid’s blood and store it over e-mail.  It has to be someone I know. -DMD291 
(non-advocate parent) 
 
Views about Re-consent 
 Nearly two-third of parents in the overall sample (n=21) felt it would be 
unnecessary or undesirable for researchers to re-contact parents to obtain 
informed consent each time they wanted to use a child’s health data in new 
research project if the parent had already given informed consent for its use in 
research.  This belief was expressed by roughly equal numbers of parent 
advocates and non-advocate parents and was voiced much more frequently by 
parents of children with CALD and DMD than by parents of children with SCD 
(n=7 of 12 CALD parents and n=11 of 12 DMD parents compared to n=3 of 10 
SCD parents).  Many parents who believed that re-consent would be unnecessary 
or undesirable cited a desire to reduce barriers to research as the reason.  Others 
felt it would be onerous for them to be contacted by researchers repeatedly.  
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Several parents of children with DMD or CALD believed a preference for re-
consent was petty or paranoid: 
 
I don’t know why people freak out about the data.  Who gives a crap? I 
just wonder why people waste so much time and energy into 
getting/needing permission.  Come on.  I mean, we are trying to save lives 
here.  So I couldn’t care less.  –DMD203 (parent advocate) 
 
 A minority of parents in the overall sample (n=7) expressed a strong preference 
for having researchers ask them for re-consent each time their child’s health data was 
used in a new research project; similar numbers were parent advocates (n=4) and non-
advocate parents (n=3).   Most parents who held this view were parents of children with 
SCD (n=5 of 10 SCD parents).  Several of them justified this preference by describing it 
as a way to avoid repeating the historical mistreatment of African Americans in U.S. 
human subjects research.   Two parents who stated a preference for re-consent were 
parents of children with CALD.  Parents’ most common reasons for desiring re-consent 
were to retain some control over the use of their child’s data and a wish to stay  informed 
about the research being conducted for their child’s condition.  Three parents of children 
with SCD also cited a preference for re-consent to respect their child’s future ability to 
make his or her own decisions about research participation.  For example: 
 
 Right now while he’s a child I’m trying my best to protect him every way I 
can, and I don’t know how he’s going to feel when he gets older, like what if he 
doesn’t want everyone in the world to know he has sickle cell anemia?  I’m just 
trying to make sure I’m making the best decisions possible for him…so if I don’t 
have control over it, or if I feel I don’t have control over it, maybe I should just 
hold off for a little while, until he gets a little bit older and we can talk about stuff 
like that.  -SCD309 (non-advocate parent) 
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 When probed, parents with different preferences about re-consent expressed some 
shared values.  For example, several parents who expressed the belief that re-consent was 
undesirable because it would hinder research also expressed a desire to remain informed 
about research for their child's condition and/or valued some way of opting out of 
research.  One parent who did not believe re-consent was necessary suggested a tiered-
consent system: 
 
 It’s a lot of administrative burden for researchers to go back continuously 
to every parent and say ‘Here, can I have permission for this piece of this, that 
piece of that’.  But as a parent, yeah, I would want to know.  Keep me informed 
and keep me in the loop, and let me make some decisions.  There might be the odd 
thing I would want to say no to.  Like if I thought the value of where that data is 
going is not where I want it to go, then yeah, I feel like I should have the 
opportunity to say no.  Like maybe you could put data in there and have a 
checklist, like ‘these are the types of things I consent to, but this I definitely don’t 
want.’ Something as proactive as possible up front, to avoid the re-consenting.  -
DMD261 (parent advocate) 
 
Views about Acceptable Research Uses of Children’s Health Data 
 Many (n=17) parents found it difficult to articulate what types of research a 
biorepository should be used for and either hesitated or required prompting when this 
question was asked. Nearly one-third (n=10) of parents (roughly equal proportions 
advocates and non-advocates) expressed the view that research priorities should be 
determined by professional scientists, with several expressing that they did not have the 
technical expertise to suggest types of research for which biorepository research should 
be used (DMD n=5 of 12; CALD n=6 of 12; SCD n=3 of 10).   
 Parents in all three disease groups (n=18) expressed a belief that parents’ ideas 
about research priorities are shaped by their own experiences with their child’s disease, 
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making research priority-setting an especially challenging topic for parents to weigh in 
on.  This seemed to be especially challenging for groups whose children have a disease 
with variable expression: 
 
 I think if we had found out that my son were too far progressed for the 
transplant, I would have been pushing very hard for newborn screening.  If he 
were eligible for the transplant, I think my focus would have been on the bone 
marrow transplant.  But his most immediate life threat is adrenal insufficiency, so 
I tend to focus on that, because I feel like that’s something that can affect all of 
our boys, immediately.   Any day.   I think it can cause a bit of tension in the 
community just because, we can all get very passionate about our own focus and 
the reasoning behind that focus.  Sometimes our personal biases can, I dunno – I 
hate to say pit us against one another, but maybe make us not quite so open to the 
other parent’s view.  –ALD160 (non-advocate parent). 
 
 In the CALD cohort, more than half of parents also expressed a view that 
newborn screening is more important than supporting research for CALD, because of a 
belief that disease prevention efforts are more hopefuly than any of the current proposed 
approaches for treating CALD.  In general, newborn screening was the most common 
advocacy issue discussed by CALD parents. 
 Parents held different opinions about the acceptability of using their child’s health 
data for research on a condition other than the one affecting their child.  Nearly half of 
parents in the overall sample (n=15) said they would not mind this or thought it would be 
actively desirable for their child’s data to be used in research on a condition other than 
the one their child had.  A roughly equal number of parents (n=14) expressed discomfort 
with the idea of their child’s data being used in research for conditions other than their 
child’s.  Parents of children with SCD (n=7 of 10 SCD parents) were more likely to take 
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exception to non-SCD research than they were to view it as acceptable or desirable (n=3 
of 10 SCD parents). 
 When probed, a few parents admitted that if they did contribute their child’s data 
to research for other conditions, they would prefer if that research stood some chance of 
benefitting people with their child’s disease: 
 
Like I said, a lot of studies are for cancer-related concerns really, and sickle cell 
has benefited from that, from those research efforts, so that wouldn’t bother me. 
As long as I can tell that there would be some benefit. If, in their stated goals for 
the research or hypotheses that somehow this would have a hand in sickle cell, I 
would go for it. I would hope that there would be some kind of benefit from this 
research to sickle cell patients. -SCD313 (parent advocate) 
 
Trustworthiness 
 Nearly two-thirds of parents in the overall sample (n=20) reported that they 
trusted researchers with whom they had a personal connection, or who had a personal 
connection with children with their child’s condition.  This theme was referenced by both 
non-advocate parents (n=12 of 18 non advocate parents) and parent advocates (n=8 of 16 
parent advocates) and across all three disease groups. The value of having a personal 
connection to affected children was a reason why many parents believed that their 
doctors were ideally situated to discuss research opportunities with them.    
 Nearly two-thirds of parents in the overall sample (n=19) also believed that an 
affiliation with a reputable institution was a marker of researcher trustworthiness.  This 
theme was referenced commonly by both non-advocate parents (n=11 of 18 non-advocate 
parents) and parent advocates (n=8 of 16 parent advocates) and across all three disease 
groups.  When probed for further detail about the characteristics that made an institution 
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reputable, parents cited an institution’s transparency and visibility as characteristics they 
associated with high repute.  As an illustration, several parents mentioned that they would 
not have enrolled in this interview study if it had not been run by investigators at Johns 
Hopkins.  While most parents said they would trust researchers from the government, 
industry, or academic medical centers equally, a handful of parents in all three groups 
mentioned some mistrust of government research, related either to their own political 
beliefs or historical transgressions of research ethics. 
 Nearly half of parents in the overall sample (n=15) said that “good 
communication” was a hallmark of a trustworthy researcher.  When probed, several 
parents explained that “good communication” entailed using clear, comprehensible 
language, being honest and transparent, or expressing respect to parents of affected 
children.  In the words of one SCD parent: 
 
They have to take the time to get to know the patient and get to know the family 
unit. The fact that they do not assume that you can’t understand what is going on 
with your child, and that they interact with you. And the fact that they not only are 
researchers but they are treating physicians, too. For me it was that they don’t 
have sickle cell, God bless them, but they were totally immersed in sickle cell, but 
they are so dedicated to trying to help my child and myself. So it is the 
communication, it is the dedication it is the sincere interest in trying to make 
things better. It is the long hours, and that I know they missed their own family 
events trying to attend to it. A lot of medical professionals do that. It is the sitting 
down saying thank you for coming, you know. It is about that interaction and 




 This study sought to understand the experiences and views of parents of children 
with rare diseases with respect to research in general, and in terms of whether and how 
their more specific views about biorepository research were related to their degree of 
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formal involvement in advocacy.  In this study, parents’ views about research appeared to 
be more related to the nature of their child’s disease than to their degree of advocacy 
experience. These findings contribute to the literature on public attitudes to biorepository 
research by shedding light on the perspectives of parents of children with rare diseases, 
which have not been extensively studied thus far.    
  
Experiences and Views Related to Medicine and Research in General 
 Most parents in this study initially understood the term “research” to refer to 
clinical trials. While parents’ general views about research did not differ notably by 
advocacy status, some views appeared to be related to their child’s diagnosis.  For 
example, consistent with the findings of Burstein and colleagues’ (2014) study of 
parental attitudes to research data sharing, parents of children with DMD and SCD were 
worried about making decisions about research data use that their children might disagree 
with when they were older.   This theme was not expressed by CALD parents, most likely 
because children with CALD usually die in childhood.   
 In addition, parents of children with SCD expressed less trusting and more risk-
averse attitudes to research than parents of children with DMD or CALD.  For example, 
SCD parents were most likely to want researchers to obtain repeat informed consent each 
time their child’s data was used in a new study.   In a handful of instances, these attitudes 
were explicitly linked to the history of systematic mistreatment of African Americans in 
U.S. research and healthcare.  This finding is consistent with a large body of literature 
showing that African Americans in the U.S. are somewhat more reticent to participate in 
genomic research owing to a history of mistreatment from researchers21–23.  In SCD 
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families, this mistrust of research institutions may be compounded by the common 
experience of being mis-treated or under-treated for chronic pain24.  These observations 
are reminders that historical and social contexts are critical in shaping research 
participants’ perceptions of research. 
 
Experiences and Views Related to Biorepository Research 
 With respect to their views about specific practices in biorepository research, 
parent advocates did not express any views that systematically differed from those of 
non-advocate parents.   Regarding research recruitment, most parents said they would 
prefer to be told about a research biorepository in-person, by the specialist managing their 
child’s care.  This finding is consistent with what Bendixsen and colleagues (2016) found 
in a focus group study enrolling parents of children with DMD, in which the authors 
learned that parents especially valued face-to-face communication and in-depth 
conversation about research.   
 Given that parents also said that personal connectedness and communication were 
hallmarks of a trustworthy research relationship, it is not surprising that most parents 
preferred to hear about research from the physicians they trusted and knew well. Indeed, 
physician-specialists caring for rare disease patients may be ideally-situated to engage 
parents in rare pediatric disease research, because of their access to relatively large 
numbers of affected families, their knowledge about a condition, and their ability to 
gauge the emotional appropriateness of approaching and recruiting parents.  This being 
said, several studies have found that while physicians can serve as bridges between 
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research and clinical realms, they may experience problematic role conflicts that require 
special training to be able to navigate25,26. 
 Most parents felt that reconsent would be unnecessary or not desirable for 
secondary uses of their children’s research data.   Their most common reason was a belief 
that re-consent would unduly hinder research.   However, when probed, many of these 
parents said they would want to receive periodic updates about how their child’s 
information was being used.   The minority of parents who felt that re-consent for 
secondary research was necessary or desirable (mostly parents of children with SCD) 
expressed similar values.  Staying informed about research opportunities for their child 
and holding researchers accountable for conducting high-quality, ethical research were 
the main reasons why some parents valued the practice of re-consent.  
 Interestingly, these results suggest that parents have a desire to “stay in touch” 
with researchers, irrespective of their beliefs about the necessity of reconsent for 
secondary data use.  Seeking repeat informed consent for secondary research uses of data 
may not be the only way to respect parents’ underlying desire to hold researchers 
accountable while remaining abreast of research activity related to their child's disease. 
The more general biobanking literature documents a wide range of parental views about 
the necessity of re-consent for secondary research uses of pediatric research samples, 
with some studies showing a majority preference for re-consent27,28 and others reporting 
the opposite finding29.  Future studies might examine whether parents’ preferences 
related to re-consent are influenced by the degree of ongoing communication they have 
with a biobank containing their child(ren)’s samples or data. 
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 With respect to their views about research priorities, many parents found it 
difficult to articulate precisely what they thought a research biorepository should be used 
for.  Parents in all three disease groups felt that parents’ ideas about research 
biorepositories are shaped by their personal experiences with their child’s disease, 
making it hard for parents with different experiences to see eye-to-eye about which topics 
are most important.  These results echo the findings of Silverman (2008) and Pelicano 
and colleagues (2014) in the context of autism research30,31.  Both found that parents of 
children with autism disagreed about which specific interventions were most important to 
test, depending on the type of autism their children had. These data suggest that patient 
engagement about research priorities may be especially challenging in the context of 
research for diseases with variable expression. 
 Irrespective of their advocacy status, most parents in this study said that they 
trusted the clinician-researchers whom they felt personally connected to, who 
communicated with them clearly and respectfully.  This finding supports prior empirical 
and conceptual work by Beach and colleagues (2007; 2015) and Elander and colleagues 
(2011) which conceptualizes trust in physicians as a product of their expressed respect to 
SCD patients32–34.  The results of this study imply that expressions of respect may also 
help to facilitate trust in researchers, even in populations that have been historically 




 This study had a number of limitations.  The parents interviewed were relatively 
highly educated, as all of them had at least some college education.  Thus, participating 
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parents may have had different views compared to those who declined participation.  
Furthermore, more female parents were interviewed in this study than male parents, 
which is another potential source of bias in our findings given evidence that there can be 
gender-based differences in attitudes to research35,36.   Finally, as mentioned earlier, 
patient advocates who were interviewed were identified because they currently occupied 
formal roles in PAOs.  It is therefore possible that the views of some advocates who do 
not work for PAOs are different from those who do and thus this study does not 
adequately represent the views of all patient advocates related to these three rare 
conditions.    
 
CONCLUSION 
   
 Parent advocates expressed few different views about research than those 
expressed by non-advocate parents.  In this study, parents’ experiences and beliefs about 
research appeared to be more closely related to the condition a child had.  Future research 
might explore whether and how disease-related differences in parents’ experiences and 
beliefs about rare disease research are ethically and practically relevant to the design of 
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MANUSCRIPT 2: Experiences and attitudes toward patient advocacy among 
parents of children with rare genetic diseases: Insights from parents with and 




Background:  For more than thirty years, patient advocacy organizations (PAOs) for rare 
genetic conditions have been involved in all aspects of health research.  Many such 
organizations are run by parents of affected children.  Little is known about why some 
parents of children with rare genetic conditions become involved in patient advocacy and 
others do not, or how parents experience and view patient advocacy generally.  Methods: 
This qualitative study interviewed parents of children with rare diseases about their 
experiences and views related to patient advocacy.  Parents with and without advocacy 
experience were interviewed.   Interview transcripts were coded and analyzed 
thematically using a combined deductive and inductive approach.  Results: Thirty-four 
parents completed interviews.  Sixteen had formal experience in advocacy organizations 
and 18 had no formal experience.  Parent advocates were motivated to be involved in 
advocacy to cope with their child’s condition, contribute skills, or by a perceived duty.  
Those who were uninvolved in patient advocacy cited their caregiving obligations, a 
desire for privacy, negative prior experiences, or a desire to protect their children as 
reasons.  Most parents thought it made sense for researchers to partner with PAOs for 
patient engagement but noted limitations to this approach.  Some parents felt that PAOs 
have difficulty collaborating with each other.  Conclusion: Both parents with and 
without advocacy roles report positive and negative experiences with patient advocacy 
organizations.  Many parents who participate in patient advocacy are motivated by 
personally compelling reasons.  However, not all patients and their families find patient 
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advocacy helpful, and some parents see limitations to using PAOs as partners for patient 





 Patient advocacy organizations (PAOs) are committed to “promoting and/or 
representing the interests of users and/or caregivers in the health arena”1.  The first PAOs 
for rare, genetic disorders were established over fifty years ago as mechanisms for 
educating the public about conditions like Cystic Fibrosis and Tay-Sachs Disease and for 
providing support to affected individuals and their families2.  In the 1980s and 1990s, as 
more genetic conditions were identified, the number of rare disease PAOs grew.  In the 
United States today, more than 250 such organizations exist3.     
 Although PAOs are heterogeneous with respect to their origins, compositions, and 
activities, the past thirty years have witnessed a clear trend of rare disease PAOs being 
highly involved in all aspects of research4.  This involvement has included fundraising for 
research, helping with study recruitment, collecting research data, assisting with study 
design, and establishing research infrastructures5,6.  Several systematic reviews have also 
found that PAOs are frequently used as partners in efforts to engage rare disease 
communities in research7,8.  Given the growing investment in patient engagement in 
research the United States, and given that researchers often turn to PAOs as their means 
of patient engagement, it has become important to examine how PAOs and patient 
advocacy are viewed by patients who are involved in advocacy and patients who are not.    
Such an understanding might help to identify advantages and disadvantages of having 
researchers partner with PAOs to engage patients in research.   
 In the United States, a disorder is considered rare if the prevalence in the U.S. is 
<200,0009.   The National Organization for Rare Disorders (NORD) estimates that there 
are over 7000 rare diseases affecting a total of ~25-30 million people in the U.S. (8-12% 
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of the population)10.  Most rare diseases are associated with life-limiting, chronic, or 
disabling symptoms, and there are few treatments for the people they affect. 
Epidemiologic data on rare diseases is scarce, and the exact prevalence of different rare 
disorders is difficult to estimate11.  An approximate 80% of rare diseases are significantly 
influenced by genetic factors and most are incurable12.  
 Much early research about the roles of patient advocates and PAOs in research 
focused on the efforts of HIV/AIDS advocates in the 1980s and 1990s.  These advocates 
challenged Federal regulations to secure patient access to early-stage experimental 
therapies and more broadly contested the social marginalization of gay men13. This early 
HIV/AIDS advocacy likely influenced patient advocates for other diseases to expand 
their work into the context of research.  Despite the influential legacy of HIV/AIDS 
activism, some sociologists and historians have questioned whether the HIV/AIDS 
advocacy movement was sufficiently inclusive to other social groups affected by the 
epidemic14, and similar concerns have been raised by social scientists who have studied 
patient advocacy for breast cancer and autism in the 1990s and 2000s when controversial 
questions about research funding allocation and the definition of disease itself splintered 
patient communities into competing factions15–18.  
 To date, only a handful of studies have examined patient advocacy for rare 
conditions.  These studies used a variety of empirical methods to uncover how advocates 
challenge conventional definitions of expertise19–22 or tensions that arise in partnerships 
between PAOs and biomedical researchers23.  Several studies have also noted that many 
PAOs generally are disease specific and are run by parents of affected children4,5.  Few 
studies have examined how patient advocacy is experienced and viewed by patients 
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and/or their family members who have and have not been involved in advocacy, or what 
drives some people and not others to become involved in patient advocacy.   
 The goal of this qualitative study was to conduct interviews about advocacy and 
PAOs with parents of children who had one of three rare, pediatric-onset genetic 
conditions:  Childhood cerebral adrenoleukodystrophy (CALD), Duchenne muscular 
dystrophy (DMD), or sickle cell disease (SCD).  The study was designed to elicit views 
from parents who have held formal roles in PAOs and parents who have not ever held 




 The methods of this study are described in detail in Appendix 2: Extended 
Methods for Empirical Study.  Using a qualitative descriptive approach, in-depth phone 
interviews were conducted with parents of children with CALD, DMD, or SCD.    This 
study was approved by the Johns Hopkins Bloomberg School of Public Health 
Institutional Review Board (JHSPH IRB).  
 
Sampling and Recruitment 
 
 Purposeful sampling was used in all three disease groups to identify and recruit 
parents who had assumed roles in patient advocacy organizations and parents who had 
never had such advocacy roles.  Eligible parents were English-speaking, residents of the 
United States with one or more affected children currently aged 0-25, or whose affected 
child(ren) were 0-25 years of age when they died.     
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 Eligible parents were notified about this study in one of three ways:  1) A flyer 
distributed in clinics at Johns Hopkins Hospital or Kennedy Krieger Institute, containing 
a link to a screening questionnaire (see supplemental materials), 2) word of mouth from 
patient advocacy group leaders who agreed to help with study recruitment, or 3) An e-
mail sent to them by a patient advocacy group for their child’s condition, containing a 
link to the screening questionnaire.  The CALD and DMD patient advocacy groups that 
helped with study recruitment were based throughout the continental U.S.; the SCD 
advocacy groups that helped were in the Greater New York and Mid-Atlantic regions 
only. 
 The online screening questionnaire was designed to learn about the nature and 
degree of parents’ advocacy involvement, in order to purposively select both advocates 
and non-advocates for recruitment. The screening questionnaire also included questions 
about parent demographics, child well-being, and the types of research enrollment 
parents had pursued for their children.  Information about these domains were considered 




 Oral informed consent was obtained before each interview.  All interviews were 
audio-recorded and transcribed either by the interviewer (LJ) or by a professional 
transcription service.   The interviews followed a guide exploring parents’ experiences 
seeking medical care for their child, experiences with and beliefs about research, 
experiences with patient advocacy organizations, attitudes toward advocacy, and views 
about biorepository research (reported elsewhere).  Before the study began, two cognitive 
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interviews were conducted with parents of children with rare diseases other than CALD, 




 The goal of data analysis was to achieve informational redundancy.  Data 
collection and analysis occurred iteratively and used a combined deductive and inductive 
approach.  The initial coding scheme was deductive, developed based on the study’s 
research questions and the domains and questions in the interview guide.  Inductive codes 
were added as new themes emerged.  A second coder was trained who coded four 
transcripts independently from the interviewer/lead investigator (LJ).  Double-coded 
transcripts were reviewed and any discrepancies discussed and resolved, and 
clarifications made to the codebook.  The coded text was entered into Atlas.ti (version 7) 




 The following section will report on data about participants' characteristics and 
advocacy roles.  Then, it will report qualitative interview findings, including data about 
parents' prior experiences with advocacy, attitudes towards advocacy, and motivations for 
being involved or uninvolved in advocacy. 
 
Participant Characteristics and Advocacy Experience 
 
 Sixteen parents with advocacy experience and 18 parents without advocacy 
experience completed interviews.  The demographic characteristics and advocacy roles of 
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parent advocates are described in Tables 1.0, 1.1 and 1.2. All participants had at least 
some college education, with over one-fourth (n=10) of parents not having completed a 
college degree.  Half of the parents (n=6) from the CALD group had lost their child to the 
disease; only one other parent had lost their child (DMD, n=1).  Parent advocates were, 
on average, older, more likely than non-advocate parents to hold a graduate degree and 
more likely to have had their child diagnosed over ten years before the interview took 
place. 
In the CALD cohort, parent advocates self-identified as either advocacy group 
founders or leaders, newborn screening advocates, or in one case, an advocacy group 
board member.  In the DMD cohort, parents self-identified as advocacy group board 
members or chairs of conference organizing committees.  One parent of a child with 
DMD was a volunteer-based public relations officer for an advocacy group, and one was 
a scientific reviewer for a patient advocacy organization that funds research.  In the SCD 
cohort, all parent advocates had founded or established small, local patient advocacy 
organizations. 
 
Qualitative Interview Findings 
 
Experiences with Patient Advocacy Organizations 
 Overall, parents were equally likely to describe positive experiences with PAOs 
as they were to describe negative experiences.  Parent advocates described their 
experiences with PAOs more often and in greater detail than non-advocate parents, with 
more parent advocates (n=10) expressing positive views than non-advocate parents (n=6).  
Notably, all parent advocates in the DMD cohort (n=6) reported having some kind of 
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good experience interacting with or being part of PAOs.  In addition, 2 of 4 SCD parent 
advocates and 2 of 6 ALD parent advocates reported positive experiences.  Six non-
advocate parents mentioned having positive experiences interacting with PAOs (n=3 of 6 
CALD non-advocate parents; n=2 of 6 DMD non-advocate parents, and n=1 of 6 SCD 
non-advocate parents).   When reporting positive experiences, parent advocates and non-
advocate parents mentioned similar examples, including: receiving emotional support 
from other parents, finding friends for their child, receiving financial support for their 
child’s medical care, and learning about research opportunities.    
 Parent advocates and non-advocate parents were equally likely to describe 
negative experiences interacting with or being part of PAOs, with the same types of 
negative experiences being cited by parents in all three disease groups and by both parent 
advocates and non-advocate parents (n=3 of 6 CALD parent advocates; n=3 of 6 DMD 
parent advocates; and n=2 of 4 SCD parent advocates and n=3 of 6 CALD non-advocate 
parents; n=3 of 6 DMD non-advocate parents; n=2 of 6 SCD non-advocate parents). The 
negative experiences described by parents included: participating in or witnessing 
arguments among parents who disagreed about how to manage their child’s condition, 
feeling depressed or emotionally drained by interacting with other affected children and 
families, not finding relevant information or help, and PAOs being disorganized or 
unresponsive.   
 Six parents of children with DMD and three parents of children with CALD 
described having a combination of positive and negative experiences with PAOs.  Four of 
these parents were advocates and three were non-advocates. 
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 Eight parent advocates (n=3 of 6 CALD parent advocates; n=3 of 6 DMD parent 
advocates; n=2 of 4 SCD parent advocates) mentioned that patient advocacy work was 
burdensome in some way, elaborating that they found advocacy work time-consuming or 
emotionally draining.   This did not deter them from being involved in patient advocacy 
but made them want to take breaks from time to time.  Some parent advocates lauded 
PAOs that allowed varying levels of involvement at different times, mirroring changes in 
the practical and emotional needs of parents and families at different stages of a child’s 
disease progression: 
 
Families still play a huge role in adulthood, and I think there’s something about 
the cyclical nature of grief that makes people need to become more involved and 
then withdraw, become more involved and then withdraw, in a cyclical way.  But I 
also feel like with Duchenne, you have this moment where you have a diagnosis 
without a lot of burdensome symptoms, for a long time, and then symptoms 
gradually become more attention-grabbing for families until it eventually many 
families find themselves in a position where they can barely get to the grocery 
store let alone think about running a fundraiser or being involved…So I think to 
have a loose structure that overlaps and allows movement works very well for the 
community.  –DMD236 (DMD parent advocate) 
  
Attitudes Toward Patient Advocacy Organizations 
 Parents also expressed some general attitudes to PAOs.  They specifically focused 
on the roles of PAOs in research engagement, their collaborative efforts, and the role of 
affected children in parent-led patient advocacy.  This section expands upon these 
themes. 
 In all three disease groups, when parents were asked if contacting PAOs was a 
good way to reach a broader sample of parents to communicate with them about research, 
most parents (n=21) said they thought that PAOs were a good place to start.  Some 
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parents (n=13) said they weren’t sure.  There were no major differences in these views 
reported by parent advocates vs. non-advocate parents.  However, of the 21 parents who 
thought that PAOs were a good place to start, seven parent advocates and two non-
advocate parents voiced a concern that some families would not be reached if researchers 
relied on PAOs alone to spread the word about research. 
 In a related theme, roughly two-thirds of parents (n = 26) in the overall cohort 
(split roughly evenly between parent advocates and non-advocate parents) expressed 
some concern about the inclusiveness of advocacy organizations.   Some specifically 
voiced a belief that participation in advocacy was difficult for socioeconomically 
disadvantaged families.  Others acknowledged that PAOs do not draw on involvement 
from all parents because advocacy is not a helpful way for all personality types to cope 
with their child’s condition: 
 
My guess would be that the advocacy groups have very specific angles, and I 
think if you reach out to a broader audience, you might be hitting more people 
with my personality and you may realize that there’s other stuff going on that the 
advocacy groups are not considering.  –CALD122 (non-advocate parent) 
 
 Roughly half of the overall sample of parents (n=16) expressed a view that PAOs 
do not collaborate effectively with one another.  This view was voiced more often by 
parent advocates than non-advocate parents and was mentioned across all three disease 
groups. It was more common for parent advocates (n=11 of 16 parent advocates) to 
believe that PAOs had deeply entrenched disagreements about which issues to support, 
which research projects to fund, which information to endorse, and which topics to focus 
on at patient conferences.   Other parents believed that disagreements between PAOs 
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amounted to little more than personality differences between advocacy group leaders.  A 
few (n=3 of 18) non-advocate parents believed that some PAOs had been established by a 
parent who wanted to raise money for his or her own child’s care, not because of any 
broader need for a new PAO.  These parents felt that the addition of multiple small 
organizations confused the mission and aims of the broader disease community:   
 
I think that parents have different objectives and different goals and they fund 
raise in their own communities and they start their own groups. I don’t like that. I 
think it complicates everything. I think it’s really, it’s just not, I don’t find it 
helpful. And again it is not something I would ever discuss with a group of women 
with kids with Duchenne. Now we’re bringing it up, like the [FOUNDATION X] 
has done a ton of awesome works, I think they advocate, they raised all kinds of 
money, they’re wonderful. But then I think, why aren’t you with [FOUNDATION 
Y]? Why are you spending all this time and money when maybe you could be 
working better as part of [FOUNDATION Y?] –DMD291 (non-advocate parent) 
 
 Five parents, four of whom were non-advocate parents (n=5 of 18), did believe 
that PAOs coordinated their efforts well.  However, when probed they had difficulty 
coming up with examples of successful collaboration among PAOs.  The remaining 
parents did not express an opinion about PAO collaboration. 
 
Reasons for Being Involved or Uninvolved in Patient Advocacy 
 Parent advocates discussed their motivations for becoming involved in patient 
advocacy, and non-advocate parents discussed the reasons for their lack of involvement.   
In some cases, parent advocates also shared their views about why they thought other 
parents are not involved in advocacy, and non-advocate parents shared their views about 
why they thought some parents were motivated to become advocates.  This section 
summarizes these themes. 
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 In all three disease groups, the most common reason parent advocates cited (n=9 
of 16 parent advocates) for being involved in advocacy was to help them cope with their 
child’s disease and/or death.  Engaging in advocacy was described as a way of turning a 
tragic situation into a more positive one or making meaning of a difficult experience.  
Several parent advocates (n=5) explained that advocacy work was therapeutic for them 
because of their proactive, goal-oriented personality types: 
 
I think it helped with our coping and our functioning. Both my husband and I are 
very goal-oriented, task-oriented people. And I think just the philosophy of 
staying busy, staying immersed, staying involved in the research community was 
just a big driver for us to kind of feel hopeful, and you know, to help do something 
about it…I mean why is it that there’s a core group of us at my children’s school 
that we follow each other from elementary, middle school and high school?  We 
are always the ones organizing this that and the other, always the ones involved, 
always the ones volunteering.  –SCD333 (parent advocate) 
 
 One parent advocate in each disease group mentioned that being involved in 
advocacy would not have helped them cope with their child’s condition in the months 
immediately following their child’s diagnosis or death.  Advocacy only became helpful to 
these parents after a period of private reflection and mourning. 
 Eight parent advocates (n=1 of 6 CALD parent advocates; n=3 of 6 DMD parent 
advocates; n=4 of 4 SCD parent advocates) said they had become involved in patient 
advocacy because they had relevant professional skills to contribute, such as scientific, 
legal, pharmaceutical, or pastoral training.  These parents had taken on roles in PAOs that 
capitalized on their professional abilities: 
 
They use me as their consumer to review drug candidates for the Congressionally 
Directed medical research program funds - they have a $4,000,000 a year pot of 
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money from that. So I did go through the process of at least being nominated into 
that, to review research grants and help allocate those funds. But that's something 
that’s because of my research background and knowledge of academics and 
research design and science. I am more comfortable helping with the research, 
rather than doing fundraising or something.  –DMD261 (parent advocate)  
 
 Several (n=5) parent advocates across all three groups described their advocacy 
involvement as a duty.   One CALD parent explained that the duty to become involved in 
advocacy originated with a promise she had made to her son before he died, in which she 
had told him that his death would not be in vain.  Another DMD parent explained that his 
sense of duty to become involved in advocacy was motivated by reciprocity, knowing 
how much help his family would need from PAOs over the course of their affected 
children’s lives. A couple of SCD parents said that their sense of duty emanated from a 
recognition that they were more socioeconomically privileged than other parents of 
children with the same condition:   
 
 I am a 38-year old woman, married with two children and a husband who works 
on federal government job and we are a tight-knit family. When I do outreach to 
parents, they're mostly single family households, they mostly don't have the type of 
income that I have, they are younger than I am, they don't really know how to take 
care of a child with the disease because their mindset…may not be the mindset of 
myself.   So I feel a duty to support them, because in the African-American 
community that is affected with sickle-cell they were not raised in a setting of 
knowing how to take care of a child at a younger age, or from a bad economic 
standpoint, let alone a child with an illness. –SCD301 (parent advocate) 
 
 Few non-advocate parents commented on why they thought other parents became 
involved in advocacy.  The four non-advocate parents who did believed that parent 
advocates used their advocacy work as a way of coping with the emotional pain, grief, 
and loss associated with raising a child with a rare condition.  In the CALD cohort, half 
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(n=3 of 6 CALD non-advocate parents) expressed a view that most PAOs for CALD are 
run by parents whose children have died from the disease. 
  
Reasons for Being Uninvolved in Advocacy 
 Nine non-advocate parents (n=5 of 6 CALD non-advocate parents; n=2 of 6 DMD 
non-advocate parents; n=2 of 6 SCD non-advocate parents) said their main reason for 
being uninvolved in advocacy was the competing burden of caring for a child with a rare 
condition.  Parents who cited this reason said that their child’s physical and emotional 
needs kept them busy 24 hours per day, or felt that their time with their children was too 
precious to sacrifice for other pursuits: 
 
I don’t have time to do this.  I’m helping my son die.  I don’t have time to – I 
probably could have gone to the family meeting in Boston during the hurricane. 
But the thought of getting stuck up there and of my husband being alone with 
[son’s name] and [his brother’s name]-  it’s not worth it, because I’m his 
caregiver. Even if he’d had a nurse, I’m still his mother. He’s dying, so I can’t 
really leave him for that long, so I do think that could be why we aren’t more 
involved.  We’re just too involved in caring for our children.   –CALD140 (non-
advocate parent) 
 
 In the DMD cohort, the most common reason parents cited for being uninvolved 
in patient advocacy (n=5 of 6 DMD non-advocate parents) was needing privacy or space 
to cope with their child’s diagnosis.  These parents had children who had been diagnosed 
between one and three years previously, and they were still deciding how publicly they 
wanted to share the news.   A handful of CALD and SCD non-advocate parents (n=2 of 6 
CALD non-advocate parents; 1 of 6 SCD non-advocate parents) also cited the need for 
privacy or space to cope as a reason for being uninvolved in patient advocacy.   These 
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parents also tended to reference their or their family members’ personality types as 
private or introverted: 
 
Not only we haven’t told our kids, we haven’t told our parents. We haven’t told 
any family. My business partner knows, and my wife has told I think one or two 
people. But we figure as soon as we told the grandparents the kids will find out so 
we just- we haven’t told anybody. It’s hard because I’d like to be more involved. I 
want to go out and try and raise money to save my son, but because we value our 
privacy, we made that decision. So we’re not actively involved in any advocacy or 
fundraising.  –DMD285 (non-advocate parent) 
 
 Seven CALD and DMD parents said they had decided to be uninvolved in 
advocacy (n=4 of 6 CALD non-advocate parents; n=3 of 6 DMD non-advocate parents) 
because they had had a negative experience interacting with other parents in a setting 
organized by a PAO.  Some of these parents viewed PAOs as spaces where parents go to 
vent or argue about decisions related to their child's care.  These parents had tried to 
attend PAO meetings or events but had witnessed or become involved in disagreements 
about the medical management of their child’s condition: 
 
The [other parents in the group] were unsupportive, it was almost like, 'my story 
is worse than your story.'  Or if I would say, 'this is what happened,' they would 
tell me I was wrong, like they knew everything about CALD...so they kicked me 
out of the group because I disagreed with them.  I think someone else has taken it 
over, who’s a little bit better now. It just seems like when you get involved in any 
disease, but especially a rare disease where parents don’t know about it and then 
they learn a little bit, they think they’re experts. I don’t know if it makes them feel 
better, like 'I’m doing everything for my son because I know this amount and 
you’re wrong.'  I don’t really know why, but it’s just not a supportive group. --
CALD140 (non-advocate parent). 
 
 
 Other parents' negative experiences were related to how hard they found it to 
watch other parents express emotion about their child's condition.  Watching other 
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parents struggle to cope with a diagnosis elicited strong feelings of aversion from some 
parents.  For example, one DMD parent stated:  
 
When I do go to some of these conferences and meet with other people, I cannot 
sit around and watch other people’s kids. I just can’t do it. It’s overwhelming. 
There’s a woman sitting next to me who has got a three-year- old, and she’s 
crying so hard she can’t even speak; she can’t get through a sentence. And she’s 
got a brother approximately 20-years-old who is in and out of the hospital, he 
can’t breathe, and their mom doesn’t even know what to tell the ambulance when 
it comes. And I just think, oh my God, I just don’t think any of that is worth our 
time. I really don’t. So no, I don’t really get too involved.  –DMD291 (non-
advocate parent) 
 
 Some non-advocate parents stated they were uninvolved in advocacy to protect 
the normalcy of their child’s life during the early stages of his or her diagnosis.  This 
reason was mentioned by DMD and SCD parents only (n=3 of 6 DMD non-advocate 
parents; n=3 of 6 SCD non-advocate parents).  These parents believed that interacting 
with advocacy organizations would prematurely impose a “disabled” or “abnormal” 
identity on their children.  Parents who mentioned this reason tended to have children 
whose DMD or SCD was in the early stages of progression: 
 
I’m really, really just focused on trying to get him a normal life so to speak…and 
not focus too much on making his life be all about this disease. I want him to 
realize with Sickle Cell Anemia he still has a life to live, and we don’t want him to 
solely focus on this thing, don’t let it affect every aspect of your life.  As he gets 
older and learns more about this disease himself, maybe we will get more 
involved in things like that, because maybe he would want to get in contact with 
people that can share in his pain or whatever it is that he’ll need support for. 
Maybe as he gets older we would be doing more of those things but right now we 
just try to treat him just like our oldest son. –SCD309 (non-advocate parent) 
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 Six parent advocates (n=3 DMD parent advocates; n=2 ALD parent advocates; 
n=1 SCD parent advocates) believed that some parents chose not to become involved in 
advocacy because of a quieter personality type or having more private, introverted coping 
styles.  Four parent advocates (n=2 DMD parent advocates; n=2 SCD parent advocates) 
believed that parents with relatively low incomes might not be able to find the time to 




 The aim of this study was to learn about the experiences and views of advocate 
and non-advocate parents regarding patient advocacy, including their perceptions of 
PAOs and their motivations for being involved or uninvolved in patient advocacy.   
 Both parent advocates and non-advocate parents reported both positive and 
negative experiences with PAOs, with more parent advocates citing positive experiences 
than non-advocate parents.  Parents reporting positive experiences appreciated that PAOs 
allowed them to meet other families dealing with their child’s condition, to access 
resources, and learn about research.  Parents reporting negative experiences described 
feeling judged by other parents, or recalled the emotional strain of interacting with other 
children and families who were openly struggling to cope with their child’s diagnosis.  
 Most parents believed that PAOs are reasonably well-equipped to help researchers 
engage patients in research, with some limitations.  One such limitation was that PAOs 
may not be able to make research involvement accessible to socioeconomically 
disadvantaged parents, because those parents may lack the time or motivation to become 
involved with PAOs.  This concern was raised more often by parent advocates than non-
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advocate parents, suggesting that parents involved in advocacy are concerned with the 
inclusiveness of their own efforts.   In the patient engagement literature, there is some 
evidence that people with addiction problems, low levels of formal education, 
undocumented citizenship, complex support needs, advanced age, or minority status are 
less likely to be included in efforts to involve members of the public in healthcare and 
research24,25.  Future studies should compare the demographic characteristics of patient 
advocates and non-advocate patients to shed light on whether partnering with PAOs for 
patient engagement could potentially perpetuate or ameliorate these patterns of non-
involvement. 
 Another general perception parents mentioned was that PAOs do not always 
collaborate well with one another.  These findings corroborate earlier literature on patient 
advocacy for conditions like breast cancer and autism, in which a lack of smooth 
collaboration between PAOs has been documented17,18.  
  Some parents found that participating in advocacy helped them to cope with their 
child’s illness, while others did not.  This finding is consistent with a growing body of 
conceptual and empirical literature which suggests that individuals adopt divergent 
strategies to cope with a genetic or other serious condition26–28.  While some find social 
interaction and problem-solving to be therapeutic, others may need time to themselves. 
 The finding that some parents were motivated to become involved in advocacy 
because they had specific professional skills is supported by a literature which shows that 
many patient advocates draw upon both formal and informal expertise6,23,29.  On the one 
hand, patient advocates who have both experiential and professional expertise may help 
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to balance out the knowledge asymmetries between “researchers” and “patients” that 
some researchers have identified as challenging to patient engagement initiatives19,32. 
On the other hand, there is evidence that the hybrid nature of patient advocates' expertise 
may raise issues in research, such as conflicts of interest31.   Future studies should explore 
the opportunities and challenges that arise when patient advocates play dual roles as 
formally-skilled professionals and experiential experts about a condition. 
 The fact that many parents said they were not involved in advocacy because of 
their competing caregiver responsibilities is supported by a literature that associates a 
significant emotional and financial burden with raising a special needs child33–35.  In a 
related theme, several parents also reported that they were uninvolved in advocacy in 
order to protect their child’s right to lead a “normal” life.  These findings suggest that 
some parents may be unwilling or unable to be engaged in research for reasons similar to 
those that prevent them from becoming involved in patient advocacy.  
   
LIMITATIONS 
 
 This study had a number of limitations.  First, the parents interviewed were 
relatively highly educated; all of them had at least some college education.  Second, 
parents volunteered to be interviewed, and those participating may have had different 
views compared to those who did not volunteer to be interviewed.  This could bias the 
results of this study or affect the transferability of these findings.  Third, more female 
parents were interviewed in this study than male parents, which is another potential 
source of bias in our findings given evidence that mothers and fathers may form different 
perspectives about experiences related to their child's illness36,37.  Finally, this study did 
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not interview parent advocates who do not hold formal roles in PAOs, which may have 




 The findings of this exploratory study suggest that irrespective of their advocacy 
involvement, parents have both positive and negative experiences when they interact with 
PAOs.   Most parents believed that it was a good idea to partner with PAOs for patient 
engagement in research, but a subset of parents –mostly those with advocacy experience-
- noted that PAOs may not be able to engage marginalized patients in research.  Future 
studies should explore whether partnering with PAOs for patient engagement is indeed 
associated with low inclusion of marginalized patients.  Future research should also 
identify strategies for involving marginalized patients in research and sustaining that 
involvement. 
 Many parents who participate in patient advocacy are motivated to cope with their 
child's diagnosis, to advance a cause, or to help others similarly situated.  However, some 
parents choose not to participate in patient advocacy for equally compelling reasons, 
including their caregiver responsibilities, emotional needs, or privacy preferences.  That 
some parents were uninvolved in patient advocacy for these reasons suggests that some 
parents may be unwilling or unable to be engaged in research.  These findings suggest 
that while PAOs may not always provide researchers with access to every type of patient 
they wish to engage, some patients may be difficult to engage regardless owing to the 
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Paper 3: Why might it matter, from a moral perspective, whom researchers choose 




 There is growing support for patient engagement in research in the United States. 
Ethical arguments in favor of patient engagement emphasize that it can help to make 
research more relevant and respectful to patients.  However, from a conceptual 
standpoint, it remains unclear whether patient engagement should be considered 
representative exercise, and if so, what this means.   Drawing upon research ethics, 
political theory, and patient engagement literature, this paper explores the concept of 
representation and argues that patient engagement should be considered a representative 
exercise in which the knowledge, expertise, and descriptive characteristics of engaged 
patients reflects that of patients who are not engaged in research.  To the extent that 
engaged patients can represent the perspectives, values, and attributes of other patients, 
the entire process of patient engagement will be more effective at achieving its ethically-
important goals of making research more relevant and respectful to patients.   However, 
practical considerations and resource constraints must also shape how researchers 





In recent years, there has been growing investment in patient engagement in research in 
the United States.  Institutions including the Patient-Centered Outcomes Research 
Institute (PCORI), the Food and Drug Administration (FDA), and the National Institutes 
of Health (NIH) have initiated programs that involve patients in aspects of research 
including research priority-setting, research design, data-collection or analysis, and 
results dissemination1–3.    
 Patient engagement is an umbrella term that refers to the involvement of patients 
in research in roles other than subjects4. Patients can be engaged in research in different 
ways, to varying degrees, and at different phases of the research process, including its 
preparatory, execution, and translational phases5.  Patient engagement can also employ 
different methods, including focus groups, surveys, one-on-one interviews, or serving on 
advisory councils or research teams6,7. 
  The literature on patient engagement identifies value in its ability to produce 
higher-quality, more accountable, and respectful research8.  However, little attention has 
been paid to whether the representation of patient groups should be an explicit goal of 
engaging patients in research, or what "representation" means in this context. Without 
conceptual clarity about whether and why patient engagement is (or ought to be) a 
representative exercise, it is difficult to know whether it might matter if volunteers who 
participate in patient engagement initiatives differ from patients who are not involved.   
 In this paper, I will begin by defending literature that suggests that, from an 
ethical perspective, patient engagement has both intrinsic and instrumental value.  
However, I will point out that prior work describing the value of patient engagement says 
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little about whom patient engagement activities should engage.  Specifically, prior work 
is silent on whether engagement should be thought of as a representative exercise, in 
which differences between engaged and non-engaged patients might matter morally.   I 
will then argue that patient engagement in research should be viewed as a representative 
exercise, and that differences between engaged and non-engaged patients might matter 
most with respect to two ethically-important goals of patient engagement: the relevance 




 This analysis is the product of a review of the literatures on patient, community, 
and public engagement in research, research ethics, and of political theory literature 
related to the concept of representation.  
 The review of the literature on patient engagement revealed that there is a lack of 
guidance about the methods that should be used to identify patients to include in patient 
engagement initiatives9,10 and claims that those chosen to participate in patient 
engagement initiatives are often sampled by convenience via patient advocacy 
organizations or other accessible populations11.   The patient engagement literatures also 
suggest that the concept of representation is loosely related to the goals of engaging 
patients in research; the notion of representation also is referenced in the public 
engagement and community engagement literatures9,10,12,13.    
 Much of the analysis used in this paper relies on bioethics work that describes the 
value of patient engagement as conceptualized as either instrumental or intrinsic in 
nature.  Instrumental value refers to the degree to which something contributes to a 
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worthy end, while intrinsic value refers to the degree to which something is valued in and 
of itself14.    
 Finally, a review of the political theory literature helped to clarify conceptual 
elements relevant to the concept of representation, allowing me to develop a more precise 
understanding of how the concept of representation does and does not apply to patient 




 The primary role of a researcher is to contribute to generalizable knowledge about 
health or to increase understanding of a health problem.  To accomplish this, researchers 
enroll human volunteers in studies involving experimental procedures or monitoring over 
time.  Since research can involve burdens and risks for those who participate, and since 
the primary goal of research is to benefit society and not research participants, there is the 
potential for the harms of research participation to outweigh its benefits to participating 
individuals and thus for research to be exploitative15.   
 In response to the mistreatment of research participants during the mid-20th 
century, in 1974 the U.S. Congress established the National Commission for the 
Protection of Human Subjects of Biomedical and Behavioral Research.  Through its 
landmark Belmont Report, The Commission put forward ethical principles to guide the 
conduct of human subjects research: respect for persons, beneficence, non-maleficence, 
and justice16.  
 Since the late 1970's, the Belmont principles have been further specified.  One 
highly cited framework emphasizes that scientific validity and social value (component 
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parts of beneficence) are ethically necessary to justify exposing research participants to 
risk, that fair selection of research participants (relevant to justice) facilitates the 
generalizability of research results, and that respect for prospective and enrolled research 
participants involves sustained communication with them over time17.  A later version of 
this same framework, developed specifically for research in developing countries, further 
suggests the importance of collaborative partnerships with research participants to 
minimize its exploitative potential18. 
  Several authors have pointed out that research has ethical considerations relevant 
to the treatment and well-being of communities and broader publics19–21.  The literature 
on community-based participatory research (CBPR) stresses that involving community 
members in research may be valuable from a justice perspective, because it addresses 
structural, physical and other inequities through power-sharing partnerships between 
researchers and communities22,23. The public engagement literature describes the value of 
involving members of the general public in research planning, execution, and priority-
setting, which can improve public understanding and support of research4,8.   
 The more recent literature on patient engagement focuses on partnerships between 
researchers and individuals or groups with specific diseases1,11,24,25.  While much of this 
literature describes the practical value of patient engagement in research, relatively few 
authors have explicitly made ethical arguments in favor of patient engagement (Ellis & 
Kass, forthcoming).    
 In order to explore whether differences between engaged and non-engaged 
patients might matter ethically, it is first necessary to clarify how patient engagement 
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advances the ethical principles of research ethics.  The following section, I will elaborate 
on the ethical value of patient engagement in research.   
 
WHAT IS THE ETHICAL VALUE OF PATIENT ENGAGEMENT? 
 
 Ellis & Kass propose a framework that maps the moral rationales for conducting 
patient engagement.  The framework distinguishes between justifications for patient 
engagement as an intrinsic act of respect and arguments that view patient engagement as 
an instrumental means of achieving more relevant, accountable, and culturally competent 
research.  
 With respect to the intrinsic value of patient engagement, Ellis & Kass argue that 
the act of listening to patients and paying attention to their concerns is in itself 
constitutive of respect for persons.  The type of respect researchers express when they 
show concern for the interests, comfort, and cultural practices of patients is an expansive 
kind of respect that goes beyond respecting a person's right to make autonomous, 
voluntary decisions about research participation.    
 This concept of respect for persons is supported by other authors.  For example, 
Dickert (2009) describes respect as “a combination of appreciating what is valuable or 
important about a person, recognizing the constraints or demands that such a valuation 
places on one’s own conduct, and acting in a way that expresses that recognition”26.   
Several other accounts of respect for persons conclude that it involves avoiding being 
rude or discourteous to others27, expressing concern for others, and listening to them and 
speaking to them directly and attentively26,29.   
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 The outcomes of patient engagement can also have moral worth.  Ellis & Kass 
provide three arguments for how patient engagement can have instrumental value.  First, 
the authors argue that patient engagement enhances research relevance.  Research that is 
relevant to patients is beneficial to them, and can be said to optimize the risk-benefit ratio 
of research and enhance its social value.  To the extent that patient input expands what is 
examined in a study, or alters how questions are asked in ways that make the research 
more meaningful to target populations, engagement can enhance relevance and in turn 
improve the benefits and value of research.  What patients believe to be a relevant 
research question or outcome may not be exhaustive of what constitutes relevant 
research, but it is clearly morally important what patients want researchers to ask and to 
measure.    
 The bioethics literature supports these claims.  For example, Casarett et al. (2002) 
consider patients' views about the relevance of a research question to be a measure of 
research value30; Grady (2002) views public perceptions of a research problem as an 
important determinant of research value31, and Wenner (2017) argues that ethical 
research should be responsive to the perceived needs of communities in order to 
minimize the risk of exploiting them32.  In CPBR (a type of research that explicitly 
commits to addressing issues that are priorities for a community) two systematic reviews 
have also found that engaging research participants increases the relevance, usefulness, 
and uptake of research results by all partners involved22,33. 
 Another outcome of patient engagement in research described to be 
instrumentally valuable is engagement better informing researchers how to express 
respect to prospective and enrolled study participants.  Respect for prospective and 
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enrolled research participants, defined broadly as a concern for their dignity and well-
being, it is suggested, can only be expressed to the extent that researchers are aware of 
what constitutes dignity or well-being to a particular set of patients or in a given cultural 
context.  Because social meanings are varied and multiple, it may not always be clear 
how researchers should specify the concept of respect, especially when researchers work 
with unfamiliar populations.  
 Evidence supports the idea that patient engagement can teach researchers how to 
express respect and that expressions of respect enhance ethically-important outcomes.  
For example, Rotimi et al. (2007) have found that community consultation resulted in the 
development of four different informed consent processes tailored to the distinct needs 
and sensibilities of different cultural groups enrolled in the same genomic ancestry 
study;34 Baker et al. (2016) found that patient engagement can help researchers learn how 
to use respectful labels for patients in situations where patients' preferences may differ 
from nomenclature scientists would otherwise use35. 
 A third outcome of patient engagement that Ellis & Kass highlight as 
instrumentally valuable is that engagement can enhance the transparency and (relatedly) 
the accountability of researchers and their study-related actions to participants8.  
Transparency refers to researchers making information visible and accessible to study 
participants, for example, about what they are doing in the study and why; accountability 
refers to researchers being answerable for their actions, and in particular for fulfilling the 
actions they promise to fulfill or achieving the goals they claim the research will 
accomplish.  Accountability, for example, may include returning to participants later in 
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the study and describing how their input changed the study or why input was not 
ultimately used.   
 This paper will focus on three of the types of ethical value patient engagement 
has:  its intrinsically respectful nature, its ability to make research more relevant to 
patients, and its ability to make research more culturally competent by helping 
researchers learn how to respect unfamiliar patient groups.   As I will argue later on, 
differences between engaged and non-engaged patients might matter with respect to these 
aims of patient engagement in research. 
 
WHAT IS MISSING FROM THE ELLIS & KASS FRAMEWORK? 
 
 The claims made by Ellis & Kass that patient engagement can be relevant to the 
ethics of a study by potentially increasing its relevance and respectfulness are 
substantiated, as seen in the previous section, by other literature and will be taken here as 
reasonable claims.  Their framework, however, is silent about whether and why it might 
matter who is engaged.  Specifically, might it matter if the patients who participate in 
patient engagement initiatives differ from patients who do not participate?  This is a 
critical question, because patient populations are heterogeneous, and patients who 
volunteer for patient engagement initiatives might systematically differ from other 
patients in any number of ways.   
 Studies have found that heterogeneity in patient populations might impact 
patients’ views about research.  For example, there is evidence that ethnoracial 
differences may affect knowledge and attitudes about genetic research for Alzhiemer’s 
disease36; that more parents of children with autism would prioritize research to help 
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autistic children develop ‘neurotypical’ skills, while more adults with autism would not37; 
that there are gender-based differences in attitudes to animal research38; and that beliefs 
about appropriate ways to obtain research consent differ depending on the cultural 
backgrounds of the study populations in question34,39 
 This dissertation project was motivated by the idea that the ability of patient 
engagement to best uphold its ethical underpinnings might depend on which patients 
researchers choose to engage in their work.  This concern arose from the observation that 
many researchers engage patients by partnering with patients who are highly motivated, 
conveniently available or who already have specific expertise5,11. 
 
WHY MIGHT IT MATTER WHOM RESEARCHERS CHOOSE TO ENGAGE?   
 
 When addressing the question of how researchers should select patients to engage 
in research, the patient engagement literature often invokes the concept of representation 
or refers to patients who volunteer to be engaged in research as "representatives". For 
example, Workman et al. (2013) find representing the patient experience to be a 
challenging aspect of patient engagement in comparative effectiveness research; Hoffman 
et al. (2010) stress the importance of achieving balanced representation of different 
groups, including patients, in research engagement efforts, and Forsythe et al. (2015) cite 
the challenge of identifying patient representatives as a barrier to conducting patient 
engagement in PCORI research.  In her work on the role of patient advocates in research 
ethics, Rebecca Dresser (2003) also identifies "uneven quality and legitimacy of 
representation"40 as one pitfall of having patient advocates more involved in the research 
process without explicitly articulating what is morally at stake in such a shortcoming.  
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 The suggestion that researchers should consider representativeness when 
embarking on patient engagement appears linked to an implicit, underlying argument that 
differences among engaged and non-engaged patients might matter with respect to the 
intrinsic and/or instrument value of patient engagement. To better understand the link 
between representativeness, patient differences, and the ethical value of patient 
engagement outlined above, it is helpful to clarify what the concept of 
"representativeness" means in relation to patient engagement in research, and whether 
"representation" in any sense ought to be a goal of patient engagement.   
 
WHAT IS REPRESENTATION? 
 
 Political theory offers an extensive discourse on the topic of political 
representation.  Much of this literature focuses on representation in the context of a 
democratic nation-state, in which individuals are asked to represent the interests of others 
by assuming roles in government institutions.  Unlike a nation-state, the research 
enterprise is not a sovereign or political entity.  As such, patients do not have rights or 
duties of citizenship related to the research enterprise.  The political theory literature is 
nonetheless useful in clarifying the meaning of the concept of representation.  
 Representation is a complex concept including multiple elements.   In political 
theory, debates about the nature of political representation often focus on the degree to 
which it is formalistic (institutionally shaped), symbolic (based on the meanings 
representatives have for their constituents), descriptive (based on the degree of similarity 
between representatives and their constituents), or substantive (based on the expression of 
substantive interests of a group by representative members of that group)41.   
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 Another fissure in the literature concerns whether representatives should act as 
delegates (who follow the expressed preferences of their constituents) or trustees (who 
follow their own judgment about a proper course of action)42, though some authors 
consider this to be a false dichotomy.  To reconcile these two ideas, Iris Marion Young 
conceives of representation as a relationship in which representatives are considered 
separate from their constituents but are connected to them in determinate ways, moving 
from "moments of authorization to moments of accountability"43.   Hanna Pitkin puts 
forth a similar idea, arguing that the specific function of representation is to exercise 
independent judgment but with credible knowledge about what constituents want41. 
 In his analysis of representation related to citizen panels, Mark Brown organizes 
conceptual literature on representation into five domains.  The five elements distilled by 
Brown are: authorization, accountability, participation, knowledge, and resemblance44.   
In the section that follows, I will highlight these dimensions of the concept of 
representation, drawing upon additional work from political theory literature. I will argue 
that if representation is understood using these five parameters, then patient engagement 
in research should be considered a representative exercise in only a very narrow sense.  
Understanding this relatively narrow sense of representation will later help me to clarify 




 Brown describes authorization as the process of selection that determines who 
undertakes the job of representing a group.   According to Hanna Pitkin (1967), 
 65 
authorization is a formal feature of representation that says nothing substantive about the 
act of representing, or whether representatives should act as delegates or trustees.   It 
logically precedes representation, making representation possible41.  Representatives may 
be authorized to represent a group through a selection process such as nomination, 
appointment, popular vote, or random selection.   There is some disagreement about 
whether the authorization of representatives via random selection confers authority on 
them in the same ways as an election or appointment would45; however, there is general 
agreement that by instituting some technical or formal process of appointment, institution 
can recognize and therefore legitimize a representative's claim to speak on behalf of a 
group45.    
   
Accountability. 
 When a community has authorized someone to represent it, according to Brown, 
accountability requires a mechanism allowing members of that group to ensure that their 
representatives act in conformity with promises they have made.  In Pitkin's view, while 
authorization makes representation possible, accountability logically follows it41.  In the 
deliberative democracy literature, accountability is understood as a process of 
transparently justifying controversial decisions by invoking reasons that a representative's 
fellow group members endorse as relevant46.   These accounts share the notion that 
accountability involves a relationship between the members of a group and their 
representative, in which group members constrain and communicate with a representative 
in some way. 
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 The concept of accountability in this context makes the most sense in reference to 
actions taken by representatives who are authorized to act on behalf of others.  However, 
in situations where an individual has no such authorization, Jane Mansbridge argues that 
representatives can still be held accountable for what they have promised members of a 
group they will do47.  Without a formal process for selecting and re-authorizing 
representatives at periodic intervals, however, this softer form of accountability may be 
practically difficult to accomplish.   
  
Participation. 
 Brown views increased public participation in policy decisions to be a core 
component of representative democracy and describes openness to participation as a 
central feature of representation.   He acknowledges that some theorists view the concept 
of representation as antithetical to public participation, because by some accounts the 
purpose of representation is to render it unnecessary for citizens to participate directly in 
complex policy decisions.   However, to the extent that representative roles are open to a 
diverse range of group members, representation can be said to have a participatory 
dimension. 
 In a political context, a decision-making body can be said to be more or less 
representative based on its degree of openness to the participation of marginalized or 
disempowered groups.  In particular, so-called "difference theorists" including Iris 
Marion Young and Anne Phillips have argued that formal and informal barriers to 
political participation correlate with the systematic disadvantage of some groups that 
have been historically excluded from democratic institution-building and decision-
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making48,49.  They use this argument to justify measures that encourage the inclusion of 
these marginalized groups in representative political processes using quotas and other 
affirmative action policies. 
  
Knowledge and Expertise. 
 In Brown's view, the knowledge and expertise component of representation is 
related to the idea that representative institutions exist to advance the best interests of 
their constituents.  While it may never be possible for members of a group to agree about 
what is right and wrong in a pluralistic society, Brown argues that some measure of 
expertise, or knowledge, is required to distinguish between a group's reflective collective 
interests and their mere impulsive desires.  
 The uncertainty surrounding many complex policy topics means that competing 
interest groups can find evidence in support of their opposing views50.  As such, there is 
ample scope for members of an overall group to disagree about what constitutes relevant 
or legitimate expertise.  Furthermore, knowledge and expertise can be construed broadly, 
as either the products of formal, skill-based training or informal personal experience.  
 
Resemblance. 
 The final component of representation that Brown points to is descriptive 
representation, which construes representation as a function of the degree of similarity 
(resemblance) between the representative and those she represents.  This type of 
representation has been resoundingly unpopular with normative political theorists owing 
to its lack of substantive content.   Descriptive representation is fundamentally concerned 
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with who the representative is, not what he or she wants or does.  As Jane Mansbridge 
describes it, it is an "essentialist model in which representatives are viewed as 'typical' of 
their constituents by virtue of sharing some discernible characteristic"51.   
 In any context, descriptive representation is problematic because individuals 
belong to multiple statistical categories and define themselves and the groups they belong 
to in variable ways.   However, there is some sense in which shared characteristics (such 
as ethnicity or gender) may correlate with what Iris Marion Young calls "social 
perspectives", defined as shared experiences that give rise to shared questions and 
concerns, if not interests or preferences43. Social perspective, in Young's view, does not 
contain determinate content (and thus is different from an interest or substantive opinion 
on an issue).  
 
IN WHAT SENSES SHOULD PATIENT ENGGEMENT BE CONSIDERED A 
REPRESENTATIVE ACTIVITY?   
 
 In considering whether representation should be considered a goal of patient 
engagement, it is important to remember two of the reasons that patient engagement has 
ethical value in the first place:  First, patient engagement has potential to make research 
more relevant to patients and second, it has potential to make research more respectful to 
patients.  As argued earlier in this paper, patient engagement in research can make 
research more respectful because listening to patients is an intrinsic act of respect and 
because patient engagement can teach researchers how to express respect to patients 
through specific words, actions, and behaviors.   
 There is most obviously a link between the knowledge/expertise dimension of 
representation and these ethical goals of patient engagement.  Here, "knowledge" is 
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construed broadly to include the experiences, perspectives, and values patients have 
regarding their health condition.  If patient engagement is intended to teach researchers 
about what matters to patients, then it follows that it will be a more successful exercise if 
patients who volunteer to give researchers their input are familiar with the experiences 
and views of a wide range of patients.   Since another ethically important goal of patient 
engagement is for researchers to learn how to demonstrate respect to patients by being 
culturally competent, it also matters how much engaged patients know about the  range of 
values and cultural practices among patients in a given patient group. 
 Yet incorporating the full range of experiences, values, and perspectives that 
patients have with respect to research can be challenging because patients with the same 
disease often differ from one another with respect to certain sociocultural and disease-
related experiences.  Health conditions affect patients in varied ways, and socioeconomic, 
cultural, geographical, or educational differences can affect how patients form views 
about research priorities relevant to their disorder.   For example, an early-stage patient 
with muscular dystrophy who lives in New York City may face very different mobility 
challenges than an advanced stage muscular dystrophy patient who lives in rural 
Wyoming, and as such, different mobility-related research questions might be relevant to 
each of them.   While some patients interact with other affected families and are exposed 
to many impacts a condition has, others experience their health condition in relative 
isolation and may only be able to share their own sociocultural or disease-related point of 
view.  
 When a patient volunteers to give researchers input about research questions or 
study instruments, it matters from an ethical perspective whether she can credibly convey 
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the experiential knowledge and values of other patients with the same disease.   If she 
cannot, then patient engagement may be limited in its ability to do its morally important 
work of making research questions, instruments, and outcomes more relevant to a 
heterogeneous group of patients.  Furthermore, if engaged patients are only able to 
convey experiences and views of affluent or formally-educated patients, their 
engagement in research could pose justice concerns because their input could lead 
researchers to systematically ignore issues that matter to patients who are marginalized or 
disadvantaged.   
 Representing diverse patient experiences and views may be especially important 
when researchers are studying a disease with a progressive or variable disease course, or 
if a patient group is internally diverse in ways that could affect views about research 
among its members, such as religious affiliation.   Evidence suggests that patients with 
different manifestations of a disease, or different ideological influences, can have 
different ideas about research.  As data from my study showed, patients with the same 
disease may disagree about research priorities if they have experienced a disease 
differently. 
 The resemblance of engaged patients to non-engaged patients is also directly 
relevant to the ethical goal of enhancing the respectfulness of research to patients.  
Resemblance matters for two reasons:  First, engaging a sample of patients that resembles 
the broader patient group may be viewed as an act of respect to members of the different 
demographic or sociocultural constituencies within that patient group.   To varying 
degrees, patients who share similar demographic or sociocultural attributes might identify 
with each other and feel connected.  In other words, those who view religion to be a 
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meaningful aspect of personal identity might feel respected knowing that another person 
from their religious background has been listened to by researchers, irrespective of any 
similarities or differences in their substantive beliefs related to research.   
 Importantly, individuals from a sociocultural group are not guaranteed to feel 
respected just because someone who shares that aspect of their identity has been listened 
to by researchers.  However, Young's concept of social perspective helps us see that some 
characteristics (such as socioeconomic status, gender, age, or disability) are correlated 
with shared experiences that give rise to shared questions or spheres of relevance.  By 
providing a way of listening to and demonstrating concern for the social perspectives of 
diverse patients, patient engagement can be considered an intrinsic act of respect for 
diverse patients, by proxy. 
 The second reason that the resemblance of engaged patients to non-engaged 
patients matters is because researchers are more likely to learn about a wide range of 
patient experiences and attitudes if they engage a subset of patients that reflect the true 
heterogeneity of that group.  For example, if researchers wish to study a treatment for 
metastatic breast cancer in young women, they might wish to consult a group of patients 
that includes a large percentage of young African American women, because evidence 
suggests that these women bear a disproportionate burden of breast cancer at young 
ages52.  Evidence also suggests that African American breast cancer patients may have 
different views about research and cancer treatment compared to women from other 
ethnic groups53.  By failing to engage a sample of patients that truly reflects the ethnic 
and cultural composition of this patient group, researchers might miss out on important 
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insights about young breast cancer patients' attitudes and values related to breast cancer 
research. 
 Thus far, I have argued that researchers should attempt to engage patients who 
know about the experiences and values of patients from diverse backgrounds if they are 
seriously committed to making their research more relevant to an internally 
heterogeneous patient group.  I have also argued that by engaging a group of patients that 
resembles the demographic and sociocultural composition of a broader patient group, 
researchers stand a better chance of demonstrating respect to members of that group.  
Although these dimensions of representation cannot be substituted for one another, it 
stands to reason that if a small handful of engaged patients is very knowledgeable about a 
full range of patient experiences, it may be less imperative to engage a descriptively 
representative sample of patients.  Conversely, engaging a descriptively representative 
sample of patients may alleviate the need for any single engaged patient to have extensive 
knowledge of other patients' experiences and beliefs.  The point is that these two 
dimensions of representation - knowledge/expertise and resemblance - are direct shapers 
of how effectively patient engagement can function as a means to achieving ethically 
important ends. 
  What about authorization, accountability, and participation?  Patients who 
become engaged in research are often chosen because they are already known to 
researchers, they are conveniently available, or they have the motivation and ability to 
devote time to such involvement5.  Thus, patients engaged in research are not generally 
described as being "authorized" in any formal sense to speak for, or make decisions on 
behalf of, other patients.  Owing to the logical relationship between the authorization and 
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accountability components of representation, there is currently little emphasis on holding 
engaged patients formally accountable to other patients, because they are not formally 
authorized to speak on behalf of those patients in the first place.  
 However, the fact that this is the case says nothing about whether engaged 
patients should be chosen based on explicit criteria.  Since it matters from an ethical 
perspective whether the knowledge/experience and descriptive characteristics of engaged 
patients reflect those of the broader patient group they belong to, it follows that the 
selection process used to engage patients in research might matter as well.  In a research 
context, where the goals of selecting patient representatives is highly focused, the use of 
formal elections would be an impractical way to select the appropriate patients to be 
engaged.  Furthermore, formal elections would still not guarantee that engaged patients 
could provide input about a broad range of patient experiences and values.   
 Rather, having researchers publicize an explicit set of reasons for seeking broad 
patient input about research might encourage engaged patients to develop the depth and 
breadth of knowledge that researchers are asking for.  It might also justify the selection of 
certain patients with specific knowledge or expertise for the job.  For example, if 
researchers wish to engage patients to learn about all the possible side effects of a pain 
medication for sickle cell disease, it might benefit them to state explicitly that they wish 
to learn about impacts of that medication for patients across the lifespan, at all dosage 
levels.  Any patient who could not demonstrate an understanding of other patients' 
experiences with the pain medication would clearly fall short of meeting the needs of the 
engagement exercise.  The public statement of intent would help researchers stay 
accountable to the goals of their engagement exercise and would signal that patient 
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volunteers need to either develop the requisite knowledge or have their input 
replaced/supplemented by the input of other patients.  By making public researchers' 
intentions to seek diverse or descriptively representative patient input, patient 
engagement efforts would also be more transparent and accountable to broader patient 
groups. 
 Regarding the participation aspect of representation, it is true that in some sense 
patient engagement is designed to increase the participation of patients in multiple 
aspects of research.  However, increased patient participation in decision-making about 
research is not an end unto itself.  Rather, it is a means through which researchers can 
learn about how to make research more relevant and respectful to patients.  Increased 
participation without any demonstrable effect on these ethically-important outcomes has 
no moral value in and of itself. 
    
GIVEN REAL-WORLD CONSTRAINTS, HOW SHOULD RESEARCHERS 
ENGAGE PATIENTS? 
 
 In practice, there are three reasons why it may be difficult or undesirable for 
researchers to engage a diverse or representative sample of patients in research.  First, 
researchers have finite time and resources available for patient engagement and a primary 
fiduciary duty to contribute to generalizable knowledge about health.   In many instances, 
it may be challenging for researchers to execute their study in a timely fashion and 
conduct representative patient engagement.  In some cases, engaging a more 
representative sample of patients may be ethically unsupportable if it diverts resources 
from the pursuit of research itself.  Furthermore, researchers may need additional training 
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and support to help them design patient engagement efforts, and these resources are not 
always available. 
 Second, experiential differences between patients need not always undermine the 
instrumental value of patient engagement; it is merely possible that differences between 
engaged and un-engaged patients could do so.  For example, my study did not identify 
any substantive differences in beliefs about biorepository research when I compared the 
views of parents who have advocacy experience and parents who do not.  Whether 
engaged patients' views about research differ from those of non-engaged patients is an 
empirical question that researchers can explore from time to time by polling broader 
patient groups for feedback about the relevance and value of the patient input they have 
incorporated into their research plans and around particular topics. 
 Third, there is evidence that the expertise and motivation of patient advocates can 
be assets in bridging divides between patients and formally-trained scientists56,57.   
Furthermore, patient advocates may bring research-related expertise to the table and may 
be in a strong position to reach out and contact other patients by virtue of their roles in 
advocacy networks.  Evidence from my study also suggests patient advocates may be 
strongly motivated to be engaged in research as part of their advocacy work.  This 
suggests that there might be tradeoffs involved in engaging a diverse or representative 
group of patients as opposed to partnering with a potentially less diverse or representative 
group of advocates who are well-equipped to have meaningful and sustained involvement 
in a research project. 
 With these considerations in mind, to the best of their practical abilities 
researchers should employ a mixture of patient engagement methodologies.  Doing this 
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will help them balance the benefits of involving patient advocates (and other available, 
motivated patient volunteers) with input from a more representative group of patients 
using surveys, webinars, or town hall meetings.  Where researchers have only one patient 
on a planning committee or data analysis team, they might consider inviting three or four 
patients from different cultural backgrounds to participate, with the goal of demonstrating 
respect for a variety of social perspectives related to their research.  If possible, 
researchers should be explicit about the type of information they wish to learn by 
engaging patients in research, so they can later evaluate whether patient engagement 
efforts have fulfilled their intended purpose.  By paying attention to the of variability 
within a patient group and the natural progression of the disease they wish to study, 
researchers can be more attuned to potential gaps in the experiential knowledge and 
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Table 1.0: Characteristics of the Three Diseases Affecting Children of Parents in this Study 









X-linked 1/17,000 Personality 










X-linked 1/3,500 Skeletal weakness, 
cardiomyopathy, 
respiratory failure 

















ischemic stroke  




















    Mother 10 9 9 28 
Father 1 3 0 4 
Legal Guardian 1 0 1 2 
     Median Age 46 39 45 n/a 
     Race 
    White Non-Hispanic 9 11 1 21 
Black 1 0 9 10 
Hispanic 2 0 0 2 
Other 0 1 0 1 
     Educational Status 
    HS Diploma Only 0 0 0 0 
Some college 6 3 1 10 
College Degree 3 6 3 12 
Graduate Degree 3 3 5 11 
Military 0 0 1 1 
     Forms of Research 
Participation for Child*    
 Randomized Clinical Trial 0 5 0 5 
Other Clinical Trial 3 0 1 4 
Observational Research 4 8 1 13 
Social Science Research 0 1 1 2 
None 5 1 7 13 
     Deceased Status of Child 
    1 or more deceased 
children 6 1 0 7 
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No deceased children 6 11 10 27 
     Time Since Child's 
Diagnosis 
    1-3 years 4 4 0 8 
3-10 years 5 6 6 17 
10+ years 3 2 4 9 
     Geographical Region** 
    Northeast 5 4 8 16 
Midwest 1 3 1 5 
South 4 1 1 6 
West 2 4 0 6 
     *Parents may have reported enrolling their child in more than one type of 
study 
 **According to U.S. Census categories 
    
 
Table 1.2: Characteristics of Parent Advocates and Non-Advocate Parents 
 
Parents in Formal 
Advocacy Roles (n=16) 






   Mother 14 14 28 
Father 2 2 4 
Legal Guardian 0 2 2 
    Median Age 50 43 n/a 
    Race 
   White Non-
Hispanic 10 11 21 
Black 5 5 10 
Hispanic 0 2 2 
Other 1 0 1 
    Educational Status 
   HS Diploma Only 0 0 0 
Some college 4 7 11 
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College Degree 5 6 12 
Graduate Degree 7 4 11 
Military 0 1 1 
    Forms of Research 
Participation for 
Child* 
   Randomized 
Clinical Trial 2 3 5 
Other Clinical Trial 2 2 4 
Observational 
Research 9 4 13 
Social Science 
Research 2 0 2 
None 4 9 13 
    Deceased Status of 
Child 
   1+ deceased 
children 5 2 7 
Child(ren) living 11 16 27 
    Time Since Child's 
Diagnosis 
   1-3 years 1 7 8 
3-10 years 9 8 17 
10+ years 6 3 9 
    Geographical 
Region** 
   Northeast 6 11 17 
Midwest 4 1 5 
South 4 2 6 
West 2 4 6 
    *Parents may have reported enrolling their child in more than one type of study 
**According to U.S. Census categories 





Table 1.3: Advocacy Roles of Parent Advocates 
 
CALD DMD SCD 
Advocacy Group 
Leader/Founder 3 0 4 
Newborn Screening Advocate 2 0 0 
Public Relations Officer 0 1 0 
Board Member 1 2 0 
Scientific Reviewer 0 1 0 
Conference 
Organizer/Fundraiser 0 2 0 


















APPENDIX 2:  EXTENDED METHODS FOR EMPIRICAL STUDY 
 
 This qualitative study had two aims, 1) to explore the views that parents of 
children with rare diseases have about research and 2) to determine whether parents of 
children with rare diseases who are patient advocates have different views about research 
than parents who are not involved in advocacy work.  To accomplish these aims, 
qualitative interviews were conducted with 34 parents of children with either childhood 
cerebral adrenoleukodystrophy (CALD), Duchenne muscular dystrophy (DMD), or 
sickle-cell disease (SCD).  Eighteen of these parents had no prior patient advocacy 
experience, and 18 currently held formal roles in patient advocacy organizations.   
 
 
DEVELOPMENT OF MATERIALS 
  
 The materials used for this study were 1) recruitment materials (Appendix 3); 2) 
informed consent forms (Appendix 4); 3) a screening questionnaire (Appendix 5), and 4) 
an interview guide (Appendix 6).  The study materials were developed by the student 
investigator under the supervision of her faculty adviser; the protocol and all materials 
were approved by the JHSPH IRB. 
 In order to test the interview guides, two pilot interviews were conducted via 
phone.  Pilot interview testing is a good way to obtain guidance about questionnaire 
design, development, and pre-testing sequence, through post-interview discussions with 
individuals who are similar to those who will be recruited into the study1. The first pilot 
interview was conducted with a parent of a child with a rare neurological disease who is 
not involved in patient advocacy and the second pilot interview was conducted with a 
rare disease patient advocacy group leader who was not eligible for enrollment in this 
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study.  The pilot interviews were audio-recorded but not transcribed.  The student 
investigator took notes during the pilot interviews and used these notes to inform changes 
to the flow of the interview guide as well as the re-wording of some questions to make 




 Parents were eligible for inclusion in this study if they were English-speaking and 
parents/legal guardians of at least one living or deceased child aged 0-18 years of age 
who is or was diagnosed with CALD, DMD, or SCD.  Eligible parents also lived in the 
United States.  Non-English speaking individuals, individuals under 18 years of age, and 
individuals whose child died less than a year ago were not eligible to participate.   
 The section below describes the features of the three diseases that affected 
children of parents in this study as well as how the student investigator recruited parents 
into this study. 
 
 
Background Information About the Conditions Parents' Children Had 
 
Childhood Cerebral Adrenoleukodystrophy (CALD) 
 Adrenoleukodystrophy is estimated to affect 1 in 20,000 male births worldwide 
and is caused by mutations in the ABCD1 gene.  The childhood cerebral form of the 
condition (CALD) affects toughly 35% of boys born with a mutation in ABCD1.  CALD 
is a fatal condition that affects the nervous system, involving a breakdown of the nerve 
cells in the brain responsible for thinking and muscle control.  Affected boys typically 
present with ADHD-like symptoms which progress rapidly, resulting in a loss of vision, 
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seizures, personality changes, cognitive decline, and eventually a vegetative state 
followed by death (usually in childhood between ages 7-15)2.  Currently, the only way of 
treating CALD is to initiate a hematopoietic stem cell transplant (HSCT) prior to the 
onset of disease symptoms. 
 
Duchenne Muscular Dystrophy (DMD). 
 DMD is a progressive X-linked neuromuscular disorder that affects an estimated 
1:3500 live births.  The condition also typically affects boys, not girls, and is thought to 
be pan-ethnic although in the U.S. it is diagnosed most often in individuals with 
European or Latino ancestry3.  DMD is characterized by worsening muscle weakness and 
wasting due to mutations in the DMD gene, which produces an essential component of 
healthy cardiac and muscle tissue.  The average age at diagnosis is four years old, with 
most patients becoming wheelchair-dependent by age 10 and developing severe 
cardiomyopathy and pulmonary dysfunction between ages 10 and 20.  Most affected boys 
die from cardiac or respiratory failure in their second or third decade of life4.  The nature 
and speed of DMD progression can vary depending on the type of mutation a boy carries.  
 
Sickle Cell Disease (SCD). 
 SCD is an autosomal recessive hematological disorder that occurs more 
commonly in individuals of Mediterranean, Asian, and Sub-Saharan African descent.  
Although the overall incidence of SCD is unknown, it is believed to affect approximately 
100,000 individuals in the U.S.   However, among individuals of African descent, 
approximately 1 in 365 babies is born with the condition per year, most of whom are 
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detected via newborn screening.  Initially, affected babies may experience repeat blood 
infections and pain crises; these symptoms are often followed by acute pulmonary 
symptoms and a risk of stroke which peaks at around six years of age.  Children also 
experience crises of bone pain, chronic leg ulceration, and in adolescent boys, priapism 
(painful sustained erection unassociated with sexual desire) may occur. Patients can live 
into their fourth or fifth decade of life 5. In severe cases, SCD is treated with HSCT, 




 Participants were recruited into this study via two avenues: 1) Recruitment 
announcement sent via e-mail by leaders of patient advocacy organizations (PAOs) 
identified via the website of the Genetic and Rare Diseases Information Center at NIH 
and 2) Recruitment flyers distributed via clinicians in clinics at Johns Hopkins Hospital 
and Kennedy Krieger Institute. 
 To recruit parents via PAOs, the student investigator e-mailed PAO personnel 
whose contact information was publicly available via a PAO website or the GARD 
patient advocacy group directory.  The initial contact e-mail explained that a doctoral 
student in the Johns Hopkins School of Public Health was interested in recruiting parents 
of children with rare diseases into a qualitative phone interview study to learn about 
parents' attitudes to research and patient advocacy.   If PAO personnel agreed to assist 
with recruitment for this study, they were provided with a copy of the study's recruitment 
announcement and were asked to distribute it to eligible parents in a manner they 
believed would be most effective.   In total four PAOs for CALD agreed to assist with 
recruitment, two PAOs for DMD agreed to assist with recruitment, and two PAOs for 
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sickle-cell disease agreed to assist with recruitment.   The PAOs that assisted with 
recruitment for CALD and DMD served patients across the United States; the PAOs that 
assisted with recruitment for SCD served patients in Maryland and Michigan. 
 To recruit PAOs via clinics, the student investigator contacted clinicians who see 
pediatric CALD, DMD, and SCD patients at Johns Hopkins Hospital and Kennedy 
Krieger Institute.  The student investigator explained the aims of the study and provided 
clinicians and clinic staff with recruitment flyers.   For CALD and DMD, recruitment 
flyers were distributed in clinics at Kennedy Krieger Institute; for SCD recruitment flyers 
were distributed in a clinic at Johns Hopkins. 
 Since it is not known how many recruitment e-mails were sent or how many 
recruitment flyers were distributed, it is not possible to calculate a response rate for this 
study.  Furthermore, since the screening process for this study did not ask patients where 
they first heard about the study, it is not possible to calculate precisely how many study 




 This study adopted a purposive sampling approach.  Purposive sampling allows a 
researcher to build a diverse and complete sample with respect to the dimensions of 
interest in a research project6.  The specific type of purposive sampling used for this 
study was called intensity sampling, which aims to select information-rich cases for in-
depth study.   
 The primary aim of purposive sampling for this study was to form two groups of 
parents to interview.  One group consisted of parents with patient advocacy experience 
and one group consisted of parents who lacked patient advocacy experience.  The 
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secondary aim of purposive sampling was to build a sample of parents that was as diverse 
as possible with respect to demographic characteristics, geographical location, education 
level, and time since their child's diagnosis. 
 To achieve purposive sampling, the recruitment flyers for this study included a 
link to a ten-item screening questionnaire administered by Google forms.  The screening 
questionnaire was designed to assess the nature and degree of parents' prior patient 
advocacy experiences including whether they currently played a formal role in a PAO.  
The screening questionnaire also included questions about the nature and number of their 
child's prior research experiences, the amount of time that had passed since their child's 
diagnosis, and demographic information about them including their age, ethnicity, 
geographic location, educational status, and deceased status of their children.  
 To select parents to invite for interview, the student investigator first took into 
account the nature and degree of a parent's advocacy involvement.  To form a group of 
parents with significant patient advocacy experience, the student investigator chose to 
interview parents with formal roles in PAOs who described being currently active in 
some aspect of advocacy.  To form a group of parents with little to no patient advocacy 
experience, the student investigator chose to interview parents who said they had never 
been involved in advocacy work.   As a secondary consideration, the student investigator 
tried to invite as demographically diverse a sample of parents to be interviewed as 
possible. 
 A subset of parents (n=12) interested in participating in the study volunteered for 
the interview and contacted the student investigator to be interviewed without filling out 
the screening questionnaire first.  In these cases, the student investigator asked parents 
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the screening questionnaire questions verbally before proceeding with the interview to 
determine their eligibility for inclusion in one of the two groups of parents interviewed. 
  
INTERVIEW PROCEDURES AND STRUCTURE 
 
 All interviews (n=34) were carried out by the student investigator via phone; all 
interviews were conducted between October 2015-April 2016.  Participants were 
informed that the student investigator was a genetic counselor and PhD student 
conducting doctoral dissertation research about parents' attitudes to research and 
advocacy.  Prior to the start of each interview, oral informed consent was obtained.  All 
interviews were audio-recorded and transcribed either by the student investigator (n=4) or 
a professional transcription service (n=30).   
 The interview guide contained three principal domains related to parents' 
experiences and attitudes to research and advocacy for their child's condition.  The 
overall interview structure was similar for all interviews, with some deviations in the 
portion of the interview that asked about parents' diagnostic journey with their children 
for different diseases.  There was some variation in the interviews depending on the flow 
of conversation and which topics parents chose to elaborate on.   
The specific domains included in the interview guide were as follows: 
 
1) Perceptions and Experiences Related to Research:  Questions included under this 
domain inquired about whether parents had previously enrolled their child in a research 
study and, if so, what that was like; if not, why not.  Follow up questions and probes 
asked parents to describe their general perceptions of research for their child's condition, 
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including how they learn about such research.  If they had enrolled their child in a 
research study, they were asked to describe what was good or bad about their experience. 
2) Perceptions and Experiences Related to Patient Advocacy: Questions included under 
this domain asked parents to describe their experiences with and perceptions of patient 
advocacy and PAOs.  This included asking about any prior interactions they had had with 
patient advocates, any prior experiences they had had performing work for PAOs, and 
any perceptions they had of patient advocates or PAOs with a specific focus on the role 
of PAOs in research. 
3) Specific Views About Biorepository Research:  The final section of the interview 
guide inquired about parents' opinions and beliefs regarding specific aspects of 
biorepository research involving their child's data.  Using the hypothetical example of the 
National Institutes of Health's Precision Medicine Initiative 
(https://www.whitehouse.gov/precision-medicine) parents were asked to imagine that 
they were being asked to contribute their child's genomic and health record data to a 
research biorepository.  They were then asked about their hypothetical preferences 
regarding a) data stewardship and the necessity of re-consent for secondary research uses 
of their child's data; b) appropriate ways to recruit parents to participate; c) how 
children's research data ought to be used and d) their view about what made 
biorespository researchers trustworthy. 
 
DATA MANAGEMENT AND ANALYSIS 
 After each interview, the student investigator took detailed memos and filled out 
an interview summary sheet.  Interview tapes were either transcribed by the student or by 
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a professional transcription service.  Identifying information was redacted from all 
interview transcripts.  Each transcript was proofread and checked for accuracy against the 
original tape.  The content of each transcript was also reviewed with a view to how the 
student might improve the interviews and in order to identify emergent themes to probe 
in subsequent interviews.  Interviews were conducted until informational redundancy was 
reached relative to this study's research questions. 
 The approach to data analysis followed a qualitative descriptive approach and 
proceeded in an iterative fashion7.  The primary phase of analysis was mainly deductive, 
with the initial coding scheme informed by this study's research questions, the domains in 
the interview guide, and themes from the literature about biorepository research ethics.  
Inductive themes relevant to this study's research questions were identified subsequently 
as tapes and transcripts were reviewed.  The initial coding scheme was applied to four 
transcripts, and the codes and code families were then further refined and re-applied 
before finalizing a coding scheme to use on all the remaining transcripts.  Coded 
segments of text were then analyzed manually and using Atlas.ti (version 7) to identify 
patterns in the data.   
 To test the reliability of the coding scheme, a second coder who is also a PhD 
student in Bioethics and Health Policy at Johns Hopkins was trained on the coding 
scheme.  The second coder independently applied codes to four transcripts.  The double-
coded transcripts were compared and any discrepancies between the codes were 
discussed and reconciled.  All discrepancies involved the application of different sub-
codes to the same chunks of text; there were no cases where the two coders applied codes 





 In addition to being a PhD student in bioethics and health policy, the student 
investigator is a board-certified genetic counselor who worked in the Division of 
Neurogenetics at Kennedy Krieger Institute for 2 years from 2012-2014.   In that 
capacity, the student investigator clinically counseled pediatric patients with ALD and 
DMD, as well as their families.  The student investigator also previously counseled 
patients with SCD as a trainee.  Because the student developed an interest in this topic 
through her experiences as a clinician, epistemological reflexivity played a prominent 
role in all aspects of this research project.    
 Epistemological reflexivity is an approach in which a researcher must ask whether 
the desired knowledge could be obtained via other means instead of her own research 
project8.   In asking questions like this, the researcher is forced to reflect on her own 
motivations and assumptions, and their implications for the research she is conducting.  
By considering reflexivity at each stage of the research process, an investigator must 
examine her methodological and analytical decisions and make these decisions explicit, 
taking into account the context of her study and her role in that context.   Such 
considerations may add richness to qualitative research, particularly if that research is 
designed with a constructivist theoretical orientation which assumes that meanings are 
socially produced9. 
 This study used a combination of spontaneous journaling throughout the project 
and more structured memo-ing to document personal, relational, and contextual aspects 
of the student investigator's role in relation to each research question, each interview 
participant, and at each stage of data analysis. 
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APPENDIX 3: RECRUITMENT ANNOUNCEMENT 
         
 
 
STUDY OF PARENTAL BELIEFS ABOUT RESEARCH 
 
 Does your child (aged 0-17) have a diagnosis of [NAME DISORDER] 
 Are you the parent of a child who had a diagnosis of [NAME 
DISORDER] in the past? 
 
We are asking you to participate in a study of parents' involvement in 
and beliefs about research on their child's condition.  
 
You have a unique perspective — we would like to learn from your 
experience. 
 
              Participation is completely voluntary. 
 Participation involves a short online questionnaire and one 45-
60 minute interview.  
 Parents who are interested may find more information here, 
along with the online questionnaire: http://bit.ly/1glLNtI 
         
  
For more information, please contact: 
Leila Jamal, ScM, CGC 
 (347) 327-0104; ljamal2@jhu.edu 
  
This research study was approved by the Johns Hopkins School of Public 
Health IRB, protocol # IRB00006316.  The Principal Investigator for this 
study, Nancy Kass, ScD can be reached at nkass@jhu.edu. 
 
you the parent of a child who currently has,  




       Are 
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APPENDIX 4: SCREENING QUESTIONNAIRE 
 
**REMINDER: If you have any questions about this study, you may call the Johns 




1. How old are you? 
2. What disorder does your child have? 
3. Which of the following best describes your relationship to a child with this disorder?   
o Mother 
o Father 
o Other primary caregiver or legal guardian 
o Other caregiver (not primary caregiver or legal guardian) 
 
4. How long ago was your son or daughter diagnosed with this disorder? 
o Less than 1 year ago 
o 1-3 years ago 
o 4-5 years ago 
o More than 5 years ago 
 
5. Have you been involved in any of the following?  Please select all that apply: 
o Policy work related to this disorder (e.g. state or federal policy lobbying, 
legislative efforts) 
o Organizing or overseeing research for this disorder 
o Fundraising for this disorder 
o Educating the general public about this disorder 
o Other patient advocacy work (explain briefly in text box) 
o No, none of the above [IF NO, then SKIP to Q. 6] 
 
6. Which of the following best describes about how often you are involved in any of the 
above activities: 
o About once per week 
o About once per month 
o A few times per year 
o Once per year or less 
 
7. Has your child ever been enrolled in a research study?   
Yes/No, then…(Optional free text field: If so, please describe your understanding of 
what the study was trying to learn:)   
8. In what country or state do you live?  
o [Drop-down menu] 
 
9. What is the highest level of education you've obtained? 
o High school or below 
o High school degree or GED 
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o Some college 
o College/Undergraduate degree 
o Graduate degree 
 
10. What is your approximate household income (drop-down menu)? 
o Less than $100,000 per year 
o More than $100,000 per year 
 
11. How would you describe your race/ethnicity? 
o White Non-Hispanic 
o African American 
o Hispanic 
o Native American 
o Asian/Pacific Islander 
o Other (Please specify) ________ 
 
12.  Please tell me your name and how I can contact you to follow up about participating 
in an interview (i.e. please provide your phone number or email address) and what times 




APPENDIX 5: VERBAL INFORMED CONSENT SCRIPT 
 
ORAL CONSENT SCRIPT 
 
You are being asked to take part in a research study.  The purpose of this study is to 
understand your involvement in and beliefs about research on your child's rare condition.  
We hope to learn more about your prior experiences with research for your child's 
disorder and to learn more about your beliefs about how such research should be done. 
You are being asked to join this study because you are the parent of a child with a rare 
disorder.  You expressed an interest in participating in the study when you completed our 
online questionnaire.    
 
The interview portion of this study involves answering questions during one conversation 
which may occur via phone or Skype.  The interview is expected to last between 45-60 
minutes.  We would like to audio record the interview, so we can note down your words 
accurately. If you do not want to have the interview audio recorded, you may still 
participate in the interview.  Please let me know, and I will turn off the machine.   
If at any time you want to withdraw from this study please let me know, and will erase 
the tape of our conversation as well as your responses from the online questionnaire.  The 
tape of our conversation, as well as all identifying information you provided to us, will be 
permanently erased at the conclusion of the study, approximately 18 months from now. 
 
Use of your study information: We will not share the content of study interviews with 
individuals who are not on the study team.   Your name will not be used in conjunction 
with any comments you share during the interview, but de-identified quotes and overall 
themes from the interviews may be shared in the study write-up and publications.  After 
each interview is transcribed, a member of our study team will remove all individually 
identifying information from the transcript and assign a code to it.  We will store all 
interview recordings and transcripts on a password-protected computer, separately from a 
spreadsheet containing links between the codes and the names of study participants.  
 
Risks of participation:  It is possible that you may feel distressed when asked to think 
about your child's condition or prior research experiences.  There is also a slight chance 
that someone could find out about the content of our conversation due to a privacy 
breech.   
 
Benefits of participation: There is no direct benefit to you for participating in this study. 
If you take part in this study, you may help others in the future.  You will not be paid for 
being in this study. 
 
You do not have to agree to be in this study.  If you do not want to join the study, it will 
not affect your care at Johns Hopkins Medical Institutions or Kennedy Krieger Institute 
or any other medical institution.   
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If you have any questions about your rights as a research participant, or if you think you 
have not been treated fairly, you may call the Johns Hopkins Institutional Review Board 
(IRB) at (410) 955-3193. 
 
Do you have any questions about me, the research, or our interview before we begin?  
Yes___  No___ 
 
Do you agree to participate in this interview and to talk to me about your involvement in 
and beliefs about research for your child's condition?   Yes____  No____ 
 






APPENDIX 6: INTERVIEW GUIDE 
 
Thank you for your willingness to speak with me today.  As a reminder, this interview is part of 
a study examining parents' involvement in research and advocacy for their child's condition.   
This project is part of my doctoral dissertation research for a PhD from the Johns Hopkins 
Bloomberg School of Public Health.   
 
0. DOMAIN: INTRODUCTION, WARM-UP  
 
To begin with, I'd like to get to know you a little bit better.  
 
0.1) Tell me the story of how your child was diagnosed.   
0.2) How are things going for you now? 
 
1. DOMAIN:  PERCEPTIONS AND EXPERIENCES OF RESEARCH  
 
In this next part of the interview, I'm going to ask about your + your child's prior experiences 
with research. 
 
EITHER: 1.1a) You mentioned in your survey responses that your child has been in a research 
study.  Can you tell me a little bit about that experience?   
 
Probes: What was good about your experience?  What was difficult about your experience?  
What did you learn from your experience? 
 
OR: 1.1b) You mentioned in your survey responses that your child hasn't ever been in a 
research study before.  Can you help me understand why not?   
 
1.2) Have you ever been involved in carrying out or fundraising for research on your child's 
condition?  Tell me about that experience. 
 
Probes: What was good about your experience?  What was difficult about your experience?  
What did you learn from your experience?   
 
1.3) Why do you think some parents get involved in orchestrating research, while other parents 
don’t?   
 
1.4) In your view, what are the pros and cons of having only some parents involved in 
orchestrating research? 
 
1.5) Do you have any concerns about the safety of research your child might enroll in?   
 
 
2. DOMAIN: PERCEPTIONS AND EXPERIENCES OF PATIENT ADVOCACY 
 
Next, I'm going to ask you some questions about patient advocacy and patient advocacy 
organizations. 
 
2.1) In general, what does the term "patient advocacy" mean to you?   
 
2.2) Do you consider yourself to be a “patient advocate”?  Explain why or why not. 
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2.3) Have you ever reached out to (or been part of) a patient advocacy organization?  Tell me 
about that experience. 
 
Probes: What were you looking for? What was good about that experience?  What was difficult 
about that experience?   
 
2.4) Sometimes, there is more than one patient advocacy organization serving people with the 
same disorder.   
 Why do you think this happens?   
 What do you think are the effects of this are? 
 
2.5) Describe what role you think advocates and patient advocacy organizations should play in 
research on [disorder X].   
 
2.6) What do you think are the effects of having advocates and patient advocacy organizations 
involved in [disorder x] research?   
 
Probes: What are the benefits? What challenges can arise? Is there any difference having a 
patient advocate involved vs. an “average” patient with no advocacy experience?   
 
2.7) When researchers want parents' input about research, they often get it from patient advocates 
and advocacy organizations.  What are the pros and cons of this strategy? 
 
3. DOMAIN: BELIEFS ABOUT RESEARCH  
 
Now, I'm going to ask you about a specific scenario.  As you may know, the federal 
government recently invested $130 million dollars in building a national research database 
that will collect genetic and health record data from millions of people across the country.  
They are calling this the “Precision Medicine Initiative” 
 
[Check for understanding, probe for prior knowledge, note this down.  Explain more if needed] 
 
The research database will be used by both government and industry researchers to study a 
wide variety of health problems.  However, the project does not have infinite resources at its 
disposal.  As such, some difficult decisions will need to be made about how this database is 
designed and used. 
 
The Precision Medicine Initiative plans to consult members of the public about these 
decisions.  In the final section of the interview, I'm going to ask you about some topics they 
might consult the public about.   
 
Section i. Public Expertise/User-Specific Expertise 
 
3.0) What aspects of this project do you think members of the public should have a say in.   Why? 
 
Section ii. Data Stewardship 
 
3.1) Let's say a parent contributes his/her child's data to this research database.  Some people 
think that no matter what, a parent should still be asked for permission every time their child's 
information is used in a new project.  Others believe that when they contribute their child's data 
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for the first time, any researcher should be able to use that child’s data in a future research project 
as long as that data does not include personal identifiers like name, date of birth etc.   
 
 What do you think about this issue?   
 What would your personal preference be? 
 
Probes:  Does it make a difference if the data is identifiable or not?  What are the pros and 
cons of contributing de-identified data?   
 
3.2) Some people believe there should be limits on how widely a child's health data is shared for 
research.  Others believe that the more widely a child's data is shared among researchers, the 
better.   
 
 What do you think about this issue?   
 What would your personal preferences be? 
 
3.3) Some people feel uncomfortable allowing certain types of organizations to access to their 
child's health data (eg. the government, for-profit organizations).  Others don't have strong 
opinions about this.   
 
 What do you think about this issue?   
 What would your personal preference be? 
 
Section iii. Research Priorities 
 
3.4) Describe some high-priority research topics you'd like to see this database used for.   
 
Probes:  Topics related to your child's condition?  Topics unrelated to your child's condition?  
How would you rank these? 
 
3.5) As you may be aware, there are different opinions about which research topics are most 
important.  For example, some people believe research should focus on preventing the birth of 
children with genetic conditions.  Others believe research should focus on treating symptoms.  
Still others think the most important goal is to find a cure.    
 Have you come across any differences of opinion about research priorities in the context 
of research on [disease X]?  Tell me more. 
 What are your personal opinions about this issue? 
 How do you think differences of opinion about research priorities should be handled by 
researchers?  By patient advocacy organizations? 
 
 
Section iv. Recruitment 
 
3.6) What are some acceptable ways for a Research Program like this to recruit parents to 
contribute their child’s data to research? 
 
3.7) What recruitment method would be most acceptable to you, personally? 
 
Section v. Trustworthiness 
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3.8) What would a researcher need to do to earn your trust?  To lose your trust?   
 







Leila Jamal, Sc.M., C.G.C. 
2502 Foster Avenue,  
Baltimore, MD 21224 













Adult and Pediatric Cancer Genetic 
Counselor (40% effort) 
Center for Medical Ethics and 
Health Policy, Baylor College of 
Medicine  
 






Bioethics and Health 
Policy  
 
Ph.D. Johns Hopkins Bloomberg School 
of Public Health 
 
2012 Genetic Counseling Sc.M. National Human Genome 
Research Institute/Johns Hopkins 
University 




St. Johns College, University of 
Oxford 
Professional Certifications  
2013-present - American Board of Genetic Counseling  
2016 - Dissertation Award, Center for Qualitative Studies in Health and Medicine at 
Johns Hopkins University 
 
2015 - Scholarship to attend Oxford University's Translation in Healthcare Conference, 
Center for Health, Law, and Emerging Technologies at Oxford University  
 
2014 - Scholarship to attend the National Society of Genetic Counselors' Annual 
Education Meeting, Invitae Corporation 
 
2011-2013 - Sir Arthur Newsholme Doctoral Scholarship, Department of Health Policy 
and Management, Johns Hopkins Bloomberg School of Public Health 
 
Honors and Awards  
 109 
2012 - Young Investigator Award, Sage Bionetworks 
 
2011 - Best Student Abstract Award, National Society of Genetic Counselors 
 




2012-2014 Genetic Counselor, Division of 
Neurogenetics  
Kennedy Krieger Institute 
 
2007-2009 Research Associate  Harvard Business School 
2004-2007 Associate Consultant  Orion Consultants 
 
Selected Peer-Reviewed Research Articles and Commentaries  
Published 
Jamal L, Robinson JO, Christensen KD, Blumenthal-Barby JA, Slashinski MJ, Vassy 
JL, Perry, DL, Wycliff J, Green RC, and McGuire AL for the MedSeq Project “When 
bins blur: Patient perspectives on returnable results from clinical whole genome 
sequencing” (accepted for publication by AJOB Empirical Bioethics) 
 
 Winickoff DE, Jamal L, and Anderson, NR. “New Modes of Engagement for Big Data 
Research.” Journal of Responsible Innovation 0, no. 0 (June 28, 2016): 1–9. 
doi:10.1080/23299460.2016.1190443. 
 
 Hercher L and Jamal L. “An Old Problem in a New Age: Revisiting the Clinical 
Dilemma of Misattributed Paternity.” Applied & Translational Genomics 8 (March 
2016): 36–39. doi:10.1016/j.atg.2016.01.004. 
 
 Christensen KD, Vassy JL, Jamal L, Lehmann LS, Slashinski MH, Perry DL etal. "Are 
Physicians Prepared for Whole Genome Sequencing? A Qualitative Analysis.” Clinical 
Genetics, June 17, 2015. doi:10.1111/cge.12626. 
 
 Angrist M and Jamal L. “Living Laboratory: Whole-Genome Sequencing as a Learning 
Healthcare Enterprise.” Clinical Genetics 87, no. 4 (April 2015): 311–18. 
doi:10.1111/cge.12461. 
 
 Mathews DJH and Jamal L. “Revisiting Respect for Persons in Genomic Research.” 
Genes 5, no. 1 (2014): 1–12. doi:10.3390/genes5010001. 
 
 Jamal L, Sapp JC, Lewis K, Yanes T, Facio F, Biesecker LG and Biesecker BB. 
“Research Participants’ Attitudes towards the Confidentiality of Genomic Sequence 
 110 
Information.” European Journal of Human Genetics, no. 8 (August 2014): 964–68. 
doi:10.1038/ejhg.2013.276. 
 
Peer-Reviewed Case Reports/Series 
 Tunovic S, Barañano KW, Barkovich JA, Strober JB, Jamal L, Slavotinek AM. “Novel 
KIF7 Missense Substitutions in Two Patients Presenting with Multiple Malformations 
and Features of Acrocallosal Syndrome.” American Journal of Medical Genetics. Part A, 
July 14, 2015. doi:10.1002/ajmg.a.37249. 
 
 Srivastava S, Cohen JS, Vernon H, Barañano K, McClellan R, Jamal L, et al. “Clinical 
Whole Exome Sequencing in Child Neurology Practice.” Annals of Neurology 76, no. 4 
(October 2014): 473–83. doi:10.1002/ana.24251. 
 
 Gonzaga-Jauregui C, Lotze T, Jamal L, Penney S, Campbell IM, Pehlivan D, et al. 
“Mutations in VRK1 Associated with Complex Motor and Sensory Axonal Neuropathy 




2015 - Chapter 13. Ethical and Policy Issues in Clinical Genetics and Genomics 
in Lashley’s Essentials of Clinical Genetics in Nursing Practice 3rd Edition  
 
2014 - "What Do We Gain or Lose by Regulating 23andMe?", Berman Institute Bioethics 
Bulletin, available at: http://bioethicsbulletin.org/archive/what-do-we-gain-or-lose-by-
regulating-23andme/  
 




2013 - "Genetic Risk for Hereditary Cancer", Berman Institute Bioethics Bulletin, 
available at: http://bioethicsbulletin.org/archive/preventing-breast-cancer/ 
 
Selected First Author Abstracts & Invited Talks 
2016 – “Exploring the Role of Patient Advocacy Organizations in Research” (Office of 
Human Research Protections, National Institutes of Health) 
 
2015 - "The Crisis of Converging Disparities in Genomic Medicine" (American Society 
for Bioethics and Humanities Annual Meeting)  
 
2014 - "Patient Perceptions of Whole Genome Sequencing Results and Intentions to Use 




2014 - "Teaching and Learning Empirical Bioethics: Resources from the Presidential 
Bioethics Commission" (Association for Practical and Professional Ethics Annual 
Meeting) 
 
2013 - "Genomic Research in Children with Neurodevelopmental Disabilities:  Consent 
and Assent Issues" (American Academy for Cerebral Palsy and Developmental Medicine 
Annual Meeting) 
 
2013 - "Implementing the Affordable Care Act in the NYMAC Region:  Considerations 
for Families with Heritable Conditions" (New York Mid-Atlantic Newborn Screening 
Regional Collaborative Board Meeting) 
 
2011 - “Does Family History Influence Anxiety/Depression in Arrhythmogenic Right 
Ventricular Dysplasia Patients?” (National Society of Genetic Counselors Annual 





Public Policy Committee, National Society of Genetic Counselors  
 Chair, Position Statement Task Force on Clinical Genome Data 
Sharing 
 Co-chair, Position Statement Task Force on Human Germline 
Editing 
 Member, Task Force on FDA Regulation of Genomic Testing 
 
Selected Teaching Experience 
2016 – Graduate Lecturer “Research Designs for Genetic Counseling Research”; 
University of Maryland Genetic Counseling Training Program 
 
2014 and 2015 – Graduate Guest Lecturer: “Genomics in Public Health: An Overview of 
Issues in Newborn Screening”; Johns Hopkins Bloomberg School of Public Health 
 
2014 and 2015 - Graduate Guest Lecturer: "Contemporary Issues in Genome Research 
Ethics"; Johns Hopkins Berman Institute of Bioethics 
 
2014 - Undergraduate Guest Lecturer: "Practical and Ethical Issues in Genetic 
Counseling"; Duke University Course on the Past and Future of the Human Genome  
 
2013 and 2014 - Undergraduate Guest Lecturer: "Genomic Counseling: Around the Field 
in 60 minutes"; Johns Hopkins University 
 
2012 - Graduate Guest Lecturer: “The Complexities of Communicating Genetic Risk”; 




2014 - Graduate Teaching Assistant: "Ethical Issues in Public Health Policy"; Johns 
Hopkins Bloomberg School of Public Health  
 
2014 - Graduate Teaching Assistant: "Ethical Issues in Public Health Practice in 
Developing Countries"; Johns Hopkins Bloomberg School of Public Health  
 
2014 - Graduate Teaching Assistant: "Ethical Issues in Public Health"; Johns Hopkins 
Bloomberg School of Public Health 
 
Non-Didactic Mentoring 
Student Supervisor, University of Maryland Genetic Counseling Training Program  
 
Thesis Committee Member – Jenn Kohler, Genetic Counseling Sc.M. Candidate 2016 
 
Funding 
2017 - ELSI Supplement to the Centers for Mendelian Genomics, NIH Grant number: 
3UM1HG006542 - 05S1 (Co-Investigator, 100% effort) 
 
Skills  
Statistical analysis (using STATA and SPSS) 
Qualitative data analysis (using NVivo and Atlas.ti) 
Grant Writers' Seminars and Workshops - NIH Version (2014) 
 
Professional Societies and Memberships 
National Society of Genetic Counselors 
American Society of Human Genetics 
American Society for Bioethics and Humanities 
 
Personal Information 
Citizenship: United States and United Kingdom 
 
 
 
 
 
